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SUMMARY
The dog has often served as a model animal for humans in scientific studies. This is due to the fact that 
dogs are susceptible to a wide range of diseases which also affect humans. One example is cancer, a 
condition that affects dogs as well as owners. Neoplastic diseases account for 18-23 % of all deaths in 
dogs (Bonnet et al., 2005 and Jagielski et al., 2002).  
 
Mammary tumor, or tumor of the breast, is the most common tumor form in intact dogs and women 
(Im et al., 2013). Mammary tumors originate in the udder, and are classified according to their 
histological characteristics. The dog has five pairs of mammary glands, and tumors are most 
commonly found in the most cranial and caudal of the glands. Lymphoma, or lymphosarcoma, is 
defined as a malignant tumor form originating from lymphocytes. It is the most common 
hematopoietic tumor in dogs. The incidence of lymphoma may be even higher in dogs than in humans 
(Jagielski et al., 2002).  
 
Thymidine kinase 1 (TK1) is a cytosolic enzyme expressed during the S-phase of the cell cycle. It 
catalyzes the phosphorylation of deoxythymidine into deoxythymidine monophosphate (dTMP). 
dTMP is then phosphorylated into deoxythymidine triphosphate (dTTP), which can be used as a 
substrate in the salvage pathway synthesis of DNA. The availability of dTTP is the rate limiting step in 
the DNA synthesis. Measurement of the activity of thymidine kinase in serum has been utilized to 
determine prognosis and result of treatment in animals and humans with hematopoietic malignancies. 
However, some patients with solid tumors do not express elevated levels of thymidine kinase in 
serum, and this has been a problem in past studies focused on serum assays.  
 
The aim of this study is to investigate the expression of TK1 in tissue samples of lymphomas and 
mammary tumors immunohistochemically. Immunohistochemical detection of the proliferation 
marker TK1 may theoretically aid routine examination of histological samples postsurgically. Analysis 
of TK1 in tissue samples may be of use to establish minimal residual disease (MRD), and an elevated 
expression of TK1 may be indicative of a non-successful surgical treatment result.  
 
20 mammary tumors (40% benign lesions) and 17 lymphoma cases were analyzed 
immunohistochemically at the National Veterinary Institute in Uppsala, Sweden. Out of those 17 
lymphoma cases, 9 were of B-cell origin and 8 were of T-cell origin. 4 samples of normal lymph node 
tissue and 3 samples of normal udder tissue were also analyzed. The tissue samples used in this study 
had been previously fixed in formalin and were available in paraffinized sections. Tissue sections of 2-
3 µm were deparaffinized and labeled with an anti-TK1 antibody (XPA 161, clone 528-2, Arocell). A 
labelled streptavidin-biotin system was used for detection (LSABTM, Dako) and 3,3´-diaminobenzidine 
(DAB) was used as chromogen. An appreciation of the percentage of positive cells was made 
manually by light microscopy and a mitotic index simultaneously counted. The expression of 
thymidine kinase was plotted against the mitotic index to see if a correlation existed.  
 
The chosen method did not render positive results in mammary tumor cells. This was due to 
dissatisfactory signal intensity and background staining. Some staining was apparent in capsular 
lymphocytic infiltrations and in the stroma of two tumors. The median percentage of positive cells in 
lymphoma samples was 0,8% for B-cell lymphomas and 1,8% for T-cell lymphomas. The median 
value in normal lymph nodes was 1,3%. The expression of thymidine kinase was not correlated to 
mitotic index, and could not be statistically validated due to insufficient amount of samples.  
 
In conclusion, there are indications that this method could be of use on tissue samples from patients 
with lymphoma. If the method is refined, detection of thymidine kinase may be of value to detect 
minimal residual disease. However, future studies will require trials of new antibodies and perhaps the 
use of an alkaline phosphatase based system. It would also be advisable to work with live patients, in 
order to analyze serum samples simultaneously.  
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SAMMANFATTNING (SUMMARY IN SWEDISH) 
Hunden har fått tjäna som modelldjur för människan i många vetenskapliga studier. Detta beror på att 
hunden drabbas av samma typ av sjukdomar som människan. Ett exempel är cancer, som ofta drabbar 
såväl hundar som deras ägare. Neoplasier orsakar 18-23 % av dödsfallen hos hundar (Bonnett et al., 
2005 och Jagielski et al., 2002).  
 
Juvertumörer, eller tumörer i bröstet, är den vanligaste tumörformen hos intakta tikar och kvinnor (Im 
et al., 2013). Juvertumörer har sitt ursprung i juvervävnaden och klassificeras enligt histologiska 
kriterier. Hunden har 10 juverdelar (fem par), och juvertumörer återfinns oftast i de mest kraniala och 
kaudala delarna. Lymfom, eller lymfosarcom, är en malign tumörform som har sitt ursprung i den 
lymfocytära cellpopulationen. Det är den vanligaste hematopoetiska tumörformen hos hundar. 
Incidensen av lymfom uppskattas vara högre hos hundar än hos människor (Jagielski et al., 2002).  
 
Thymidin kinas 1 (TK1) är ett cytosoliskt enzym som uttrycks under cellcykelns S-fas. Det katalyserar 
fosforyleringen av deoxythymidin till deoxythymidinmonofosfat (dTMP). dTMP fosforyleras sedan 
vidare till deoxythymidintrifosfat (dTTP), som i sin tur kan användas som substrat i salvage pathway 
syntesen av DNA. Tillgången på dTTP är det hastighetsbestämmande steget i DNA-syntesen. 
Mätningar av aktiviteten av TK1 med serum som provmaterial har använts för att bestämma prognos 
och undersöka behandlingsresultat hos djur och människor med hematopoetiska neoplasier. Många 
patienter med solida tumörer uppvisar dock ingen förhöjning av enzymaktiviteten i serum, och detta 
har varit ett problem i tidigare studier där serum har använts som provmaterial.  
 
Syftet med denna studie är att undersöka uttrycket av TK1 immunohistokemiskt i vävnadsprover från 
hundar med juvertumörer och lymfom. Immunohistokemisk detektion av proliferationsenzymet 
thymidinkinas kan teoretiskt bli ett framtida hjälpmedel vid rutinmässig histologisk undersökning. 
Metoden skulle kunna ha en framtida applikation vid vävnadsundersökningar på extirperad vävnad 
efter kirurgiska ingrepp. Analys av TK1 i vävnadsprov skulle kunna vara av värde för att fastställa 
minimal residual disease (MRD) efter cytostatikabehandling, och ökat uttryck av TK1 i vävnad kan 
teoretiskt indikera att ett kirurgiskt ingrepp ej lyckats avlägsna en förändring med marginal.  
 
20 juvertumörer (40 % benigna lesioner) och 17 lymfomfall analyserades immunohistokemiskt på 
Statens Veterinärmedicinska Anstalt (SVA) i Uppsala. Av de 17 lymfomfallen var 9 B-cellslymfom 
och 8 T-cellslymfom. 4 prov från normala lymfknutor och 3 prover från normal juvervävnad 
analyserades med samma metod. Vävnadsproven hade tidigare fixerats i formalin och fanns 
tillgängliga för studien i paraffinklossar. Vävnadssnitt om 2-3 µm avparaffinerades och märktes in 
med en anti-TK1 antikropp (XPA 161, klon 528-2, Arocell). Ett streptavidin-biotin system användes 
för detektion (LSABTM, Dako) och 3,3´-diaminobenzidin (DAB) användes som kromogen. En 
uppskattning av hur många procent av cellerna som var positiva för TK1 gjordes manuellt i 
ljusmikroskåp. Ett mitotiskt index räknades också manuellt. Uttrycket av TK1 plottades mot mitotiskt 
index för att se om en korrelation mellan parametrarna förelåg.  
 
Något uttryck av TK1 kunde ej detekteras i juvertumörcellerna med den valda metoden. Detta berodde 
på otillräcklig signalstyrka i kombination med bakgrundsinfärgning. Dock kunde uttryck av TK1 ses i 
kapsulära lymfocytinfiltrat och stromat hos två tumörer. Medianuttrycket hos lymfomen var 0,8 % för 
B-cellslymfom och 1,8 % för T-cellslymfom. I normalvävnaden var medianuttrycket 1,3 %. Uttrycket 
av TK1 var ej korrelerat till mitotiskt index och kunde ej analyseras med statistisk signifikans på grund 
av otillräcklig provmängd.  
 
Sammanfattningsvis finns indikationer på att denna metod kan vara användbar på vävnad från 
patienter med lymfom. Metoden kan ha framtida användning för att fastställa MRD. Dock kommer 
framtida studier att kräva validering av nya antikroppar och kanske även ett byte till ett 
alkalinfosfatasbaserat detektionssystem. Det kan också vara av värde att arbeta med levande patienter, 
så att det blir möjligt att analysera serumprov simultant.  
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ABBREVIATIONS 
 
ABC avidin-biotin complex  
ADP adenosine diphosphate 
AgNOR argyrophilic nucleolar organizing region 
ATP adenosine triphosphate 
AZTMP 3´-azido-deoxythymidine monophosphate 
CD cluster of differentiation/designation 
CHOP cyclophosphamide, hydroxydaunorubicin, oncovin, prednisolone 
CK cytokeratin 
CR complete remission 
CT computed tomography 
DAB 3,3´-diaminobenzidine 
DLBCL diffuse large-cell B-cell lymphoma 
dT deoxythymidine 
dTMP deoxy-thymidine monophosphate  
dTTP deoxy-thymidine triphosphate 
ECL enhanced chemiluminescence  
EGFR epidermal growth factor receptor 
ER estrogen receptor 
FDG (18F)-fluoro-2-deoxy-D-glucose 
FLT (18F)-fluorothymidine 
HER2/neu human epidermal growth factor receptor 
HPF high power field 
IGH immunoglobulin heavy chain 
LDH lactate dehydrogenase 
kDa kiloDalton 
LSAB labelled streptavidin-biotin 
MALT mucosa-associated lymphoid tissue 
MDS myelodysplastic syndrome 
MRD minimal residual disease 
NK-cell natural killer cell 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PET positron emission tomography 
PR progesterone receptor 
Rb retinoblastoma protein 
TBS tris-buffered saline 
TK thymidine kinase 
TK1 thymidine kinase 1 
TK2 thymidine kinase 2 
VEGF vascular endothelial growth factor 
WBC white blood cell count 
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INTRODUCTION 
Cancer prevalence in the canine population 
Cancer is a form of disease that increasingly affects the dog population. The dog has often served as a 
model animal for humans in oncology studies. Dogs live together with their owners and are exposed to 
the same environmental factors as humans. It has been shown that the incidence of cancer in dogs in a 
specific geographical region is similar to that of the human population in the same region (Jagielski et 
al., 2002). Like humans, dogs spontaneously develop age –related diseases. Furthermore, canines are 
also susceptible to a range of diseases which coincide with the pathology of humans. However, the 
clinical development of those illnesses occurs more rapidly in dogs than in humans, which also means 
that they are easier to study. Tumor of the breast, or mammary gland, is the most common tumor form 
in women and female dogs (Im et al., 2013). 
 
4 % of dogs with life insurance die each year before the age of 10, according to the Swedish insurance 
company Agria´s statistics. 68 % of insured dogs live beyond the age of 10 according to this register 
(Bonnett and Egenvall, 2010). The average age when cancer is diagnosed in dogs is 8,8 years for 
females and 7,9 years for males according to a Danish study (Brönden et al., 2010). There is an 
increased risk of developing cancer with increasing age. The risk that a veterinary insurance case 
concerns a neoplastic disease increases from < 1 % for one year old dogs to 7 % in nine year olds 
(Bonnett and Egenvall, 2010). Neoplastic disease is the most common reason for euthanasia according 
to Agria´s statistics. In those cases where a cause for euthanasia was reported to the insurance 
company, neoplasia accounted for 18 % of the cases (Bonnet et al., 2005). In another study, neoplasia 
was reported to account for 23 % of death causes in dogs (Jagielski et al., 2002).  
 
In human medicine, cancer registries have been implemented for many years.  A cancer registry is 
defined as an organization that systematically collects information, reports and analyses related to 
various types of cancer (Nödtvedt et al., 2012). Cancer registries for canine patients are growing in 
number, and are currently being implemented in countries such as the UK, the U.S, Canada and Italy. 
A report from the Norwegian dog cancer registry shows that more than 50 % of over 6000 reported 
tumor cases were of malignant decent or potentially malignant, the Boxer having the highest overall 
tumor risk according to the referenced study (Arnesen et al., 1995). 
 
There are population-based registries and hospital-based records. The hospital-based registries 
summarize only the cases treated in a specific hospital. This implicates that an incidence rate cannot be 
calculated based on numbers from a hospital-based registry. In Denmark, the registration of dogs with 
cancer is compulsory and a web-based registry is available since 2005 (Nödtvedt et al., 2012). In the 
neighboring country of Norway, a canine cancer registry has been available since 1990. It is 
coordinated by the Veterinary School of Norway and collects information from four regions of 
Norway regarding the incidence of new cancer cases. The data is then compiled with information from 
the Norwegian Kennel Club for epidemiological purposes (Nödtvedt et al., 2012). In Sweden, the 
registry of insured dogs in Agria has been used for epidemiological studies on cancer in dogs since 
1995. Agria insures 40 % the dog population in Sweden (Bonnett and Egenvall, 2010). Using 
insurance records for epidemiological evaluation of a population is a useful tool, but has its 
limitations. It is therefore important to validate such records before they are used for research purposes 
(Egenvall et al., 2009). 
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Definitions – mammary tumor and lymphoma 
“Mammary tumor” is the collective name for tumors derived from the mammary gland or udder. 
Mammary tumors can be of benign or malignant character (Misdorp et al., 1999). However, the 
disease “mammary cancer” (equal to breast cancer in humans) is caused by mammary tumors which 
are exclusively malignant. Tumors are classified according to their histological morphology. The 
histological evaluation of mammary tumors is discussed further in Appendix I.  
 
The mammary gland is a modified sweat 
gland found only in mammals. It is derived 
embryonically from ectoderm (Pretzer, 
2008). In the dog, the development is 
initiated by the formation of two parallel 
ventral thickenings of the ectoderm, or milk 
lines. This becomes visible at 25 days of 
gestation (Pretzer, 2008).  Placodes are 
formed by migrating cells within the milk 
lines, and these eventually form the 
individual milk glands. The female canine 
usually develops 5 pairs of separate milk 
glands, although reports exist of dogs 
having 4 or 6 pairs (Silver, 1966). There are 
two thoracic (T1 and T2), two abdominal 
(A1 and A2) and one inguinal pair in the 
adult dog (Silver, 1966). Mammary tumors 
are more frequently found in T1 and the 
inguinal gland, the most cranial and caudal 
of the glands (Moulton et al., 1970).  
 
Malignant tumors in the udder have a 
tendency to metastasize to a variable extent. 
Carcinomas often metastasize through the 
lymphatic route, giving rise to daughter 
tumors in the lung, the liver, bone tissue 
and the urogenital system (Clemente et al., 
2010). In which direction the cancer cells 
spread within the udder is often determined 
by the lymphatic drainage of the udder. T1 
and T2 (no 1-2) are connected to the 
axillary lymph centre (proper and accessory 
lymph nodes). In rarer cases, T1 may 
communicate with the sternal lymph node.  
However, the recruitment of the superficial 
cervical or ventral thoracic lymph centre 
may be observed in cases of mammary 
neoplasia (Pereira et al., 2003). The 
abdominal glands (no 3-4) are drained by 
the axillary and inguinofemoral lymph 
nodes. Regarding A1, the axillary centre 
predominates. A2 is most commonly drained through the inguinal route, but it has been shown that the 
axillary and popliteal lymph node may be involved in dogs with neoplasia (Pereira et al., 2003). The 
inguinal gland (mammary gland no 5) commonly connects to the superficial inguinal lymph node and 
the popliteal lymph node. (Pereira et al., 2003). It has also been found that neoplastic mammary 
tumors more commonly communicate with the opposite side of the udder (50 % compared to 33 % in 
healty dogs). Moreover, neoplasias in the cranial abdominal gland are prone to forming 
lymphaticovenous communications, potentially enabling hematogenous spread (Pereira et al., 2003).  
 
Fig 1. Schematic illustration of the lymphatic drainage (left 
side) and sources of major arterial blood supply (right 
side) of the normal canine udder. Done free hand after 
Slatter, Textbook of Small Animal Surgery, 3rd ed and Dyce, 
Sack, Wensing, Textbook of Veterinary Anatomy,4th ed. 1. 
Proper and accessory axillary lymph nodes; 2. Superficial 
inguinal lymph node; 3. Branches of A. thoracica interna; 
4. Branches of A. epigastrica superficialis cranialis; 5. 
Branch of A. thoracica lateralis; 6. A. epigastrica 
superficialis caudalis; 7. A. pudenda externa. Arteries are 
not depiced in their entirety and their routes are purely 
schematic.  
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Malignant lymphoma (lymphosarcoma) is a heterogeneous group of tumors derived from lymphocytes 
(B cells, T cells and natural killer cells). The prognosis differs depending on the histological 
characteristics of the lymphoma. Patients with T-cell lymphoma have a shorter median survival time 
compared to patients with B-cell lymphoma (Elliott et al., 2013). Immunohistochemical detection of 
CD3 and CD79α may assist in determining whether the lymphoma is of B-cell- or T-cell decent (Valli 
et al., 2013). CD18 can identify the presence of histiocytic lineages. Lymphomas can be roughly 
divided into high-grade or low-grade lymphomas. High grade lymphoma is the most common form in 
dogs and results in death within weeks after diagnosis if treatment is not initiated (Marconato et al., 
2011). The clinical implication of a low-grade lymphoma is not as severe as for high-grade 
lymphomas, and they grow slowly. Between 5,3-29 % of all malignant lymphomas in dogs are 
indolent and are defined as low-grade. Canine patients with low-grade lymphoma have an average 
survival rate of 4,4 years after diagnosis (Flood-Knapik et al., 2012). In the study by Flood-Knapik et 
al., samples from 75 dogs with indolent lymphoma were examined. In this study, 61,7 % were T-zone 
(T-cell lymphoma, average survival time 33,5 months) followed by marginalzone lymphoma with an 
average survival time of 21,2 months (Flood-Knapik et al., 2012). Subclassification of lymphomas is 
performed microscopically, and will be further discussed in the section “Histological classification of 
mammary tumors and lymphoma” in Appendix I.  
 
 
 
Epidemiology of mammary tumors and lymphoma in the canine population 
Denmark has a national veterinary cancer registry established for the purpose of compiling case 
information regarding neoplastic diseases in the veterinary field. 1878 cases of neoplastic disease in 
dogs were reported to the registry during the time relapsed from the 15th of May 2005 to the 15th of 
April 2008 (Brönden et al., 2010). The proportion of malignant tumors was 38 %. 45 % of tumor cases 
were classified as benign and 17 % remained unclassified. Lymphoma and mammary tumors make up 
a significant part of the total number of malignant tumors. Out of the 38 % malignant tumors in the 
Danish cancer registry, 6 % were classified as malignant mammary tumors and 6% were lymphoma 
cases (Brönden et al., 2010).  
 
 
Fig 2. Schematic 
illustration of a 
normal lymph node. 
Done free hand 
after Schaller, 
Illustrated 
Veterinary 
Anatomy, 2nd ed. a. 
Efferent flow of 
lymphatics. B. 
afferent flow of 
lymphatics. c. 
Medullary region. 
d. Hilar region.  
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Mammary tumor is the most common tumor form in intact bitches (Egenvall et al., 2005). According 
to the Norwegian cancer registry, 59 % of reported tumors in dachshunds consisted of mammary 
tumors (Arnesen et al., 1995). According to another Norwegian report, the incidence of malignant 
mammary tumors in female canines among any of the breeds included in the study is 53,3 % (Moe, 
2001). Some studies have reported a higher proportion of mammary tumors, and in others they only 
make up around 40 % of the tumors in bitches (Sorenmo et al., 2009). Tumors of the reproductive 
system (including the udder) constituted 28 % of the total number of reported neoplasias according to 
a Danish study (Brönden et al., 2010). Similarly, the incidence of mammary tumors was 21,5 % 
according to a Polish study (Jagielski et al., 2002). Some studies report a range in prevalence from 28 
% to 91 % percent (Vos et al., 1993). However, this range in prevalence could be due to inconclusive 
histological grading due to lack of consensus in the previous grading systems (Vos et al., 1993).  
 
The mean age of diagnosis is 8,8 years for mammary tumors in all breeds, and 7,9 and 7,8 years in 
Boxers and Springer Spaniels respectively (Moe, 2001). The incidence of mammary tumors is very 
low among dogs younger than 2 years, and a subsequent increase is observed after 6-8 years of age. A 
peak is seen in the age-group 9-11 years, overall incidence being almost twice as high in pure bred 
dogs as it is for cross bred dogs of any age category (Dorn et al., 1968). A home-cooked diet and 
obesity at 1 year of age and 1 year before diagnosis are factors associated with the development of 
mammary tumors in dogs (Pérez Alenza et al., 1998). In the case-control study by Pérez Alenza et al., 
the risk of developing mammary tumors was positively correlated to intake of red meat, and negatively 
correlated to intake of poultry and vitamin A. Odds ratio is 2,32 of developing mammary tumors for 
female dogs treated with progestins, suggesting hormone status as a risk factor (Stövring et al., 1997). 
 
Dachshunds, Scottish terriers and Golden retrievers have been suggested to have a higher incidence of 
mammary tumors than others (Moulton et al., 1970). English Springer Spaniels, Cocker Spaniels, 
Poodles, Yorkshire Terriers, Dachshunds, Maltese dogs, Pulis, German Shepherds, English Setters and 
Pointers have been considered at higher risk of developing mammary tumors in numerous studies from 
1978-2001 (Egenvall et al., 2005). In a study on 80 000 insured dogs of 280 different breeds, Springer 
Spaniel, Dobermann and Boxer were found to be at the highest risk of developing mammary tumors 
when compared to other breeds (Egenvall et al., 2005). In this study, Golden Retrievers were not 
found to be at higher risk of developing mammary tumors. It is important to note that neutering status 
was not taken into account in this study. Poodles are more commonly affected by benign tumors, 
according to a study from 1970 (Moulton et al., 1970). It is important to note, that the validated WHO-
system of classification by Misdorp et al dates back to 1999. Bitches are 62 times more likely than 
males to develop mammary tumors. Furthermore, mammary tumors in male dogs are usually benign 
and median age of onset is 11,5 years (Saba et al., 2007). In intact dogs, mammary tumors account for 
41,7 % of all tumors and 13,4 % in spayed dogs in a study conducted in California between 1963-
1966. In this study, the overall cancer incidence in dogs was 381,2/100 000 dog years (Dorn et al., 
1968).  
 
In order to keep statistics on spontaneously occurring tumors in the dog population, the Animal Tumor 
Registry was established in 1985 in Genoa, Italy. 6743 tumor biopsies from dogs were sent to the 
registry and included in an extensive histological study in the time period 1985-2002. 48,9 % of the 
material was classified as malignant. 27,1 % of the bitches with malignant tumors were > 11 years old 
at the time of diagnosis compared to 3,1% of the bitches in the age category < 3 years. The 
corresponding figures were 30 % and 5,7 % in males, indicating a predisposition for the development 
of cancer with increasing age. Mammary tumors comprised 70,5 % of all cancer cases in bitches in 
this study (Merlo et al., 2008). 8,4 and 20,1 % of cancers were non-Hodgkin's lymphoma in females 
and in males respectively. The incidence rate for all types of canine cancers was 272,1/100 000 dog 
years at risk for females and 99,3/100 000 dog years at risk for males. This was calculated based upon 
data from the entire period. Why IR was almost 3 times higher for females than for dogs can mainly be 
explained by the high proportion of malignant mammary tumors in the female dog population (Merlo 
et al., 2008). This is supported by other studies, in which the incidence rate for mammary tumors is 
205/100,000 dog years at risk (Dobson et al., 2002).  
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Malignant lymphoma is the most common hematopoietic cancer in dogs and there are reports saying 
that lymphoma cases make up 20 % of all cancer cases in dogs (Ito et al., 2011). Other reports state 
that lymphomas only account for 5 % of all cancer cases, with an incidence of 25/100 000 dogs 
(Elliott et al., 2013). The incidence of tumors of the lymphatic system in Poland is estimated at 4,4 %. 
However, the incidence of lymphoma in dogs exceeds the incidence of lymphoma in humans 
(Jagielski et al., 2002). According to other studies, lymphoma cases make up 83% of all hematopoetic 
neoplasms, corresponding to 7-24 % of all neoplasms in canines (Sato et al., 2012). In a French study 
from 2010, 7608 biopsies of canine lymphoma cases were studied and classified according to the Kiel-
classification system. Out of the extranodal lymphomas (17,6 %), lymphoma was most often present 
in the skin (12,34 %), spleen (1,80 %), the digestive tract and the tonsils (1,48 % respectively). In this 
study, no difference was found in the distribution of age and sex in patients affected by B-and T-cell 
lymphoma. However, Boxers were overrepresented in the study. They accounted for 10,03 % of the 
lymphoma cases (compared with 2 % in France nationally). 2,32 % of B-cell lymphomas were found 
in the Boxer population,  but they were clearly overrepresented in the number of T-cell lymphoma 
cases where Boxers accounted for 24,19 % (Ponce et al., 2010).  
 
In a study conducted by Sapierzynski et al from 2010, 100 fine needle aspirates from canine 
lymphoma patients were analyzed. In this study, 44 % and 56 % were females and males respectively. 
The median age was 7,5 years, with the spread between 1,5-15 years. According to a Brazilian study, 
the most affected breed was the mixed breed, constituting 43 % of the samples in the study. The Boxer 
and German Shepherd represented 14 % and 11 % respectively, and the mean age was 8,7 years with a 
spread of 5 months to 15 years. 85 % of dogs had T-cell lymphoma, and the rest had B-cell lymphoma 
(Kimura et al., 2011). Other studies have reported a variation between 6,3-7,7 years (Teske, 1994), 
and that 60 % of lymphomas in canines are of B-cell origin (Dobson, 2004). Other studies have 
reported an increase in incidence of lymphoma with increasing age, peaking at 10 years (Edwards et 
al., 2003).  29 % of the dogs in the study by Sapierzynski presented with lymphadenopathy alone, 
while 71% of the dogs also suffered extranodal symptoms (for example, weakness, weight loss, 
fatigue, recurrent episodes of fever). As a comparison, 37 % had lymphadenopathy in the study by 
Kimura et al; 23 % had extranodal lymphoma, 20 % cutaneous lymphoma, 18 % alimentary 
lymphoma and 2 % mediastinal lymphoma (Kimura et al., 2011). In the study by Sapierzynski et al, 
14 % of the lymphomas were classified as low-grade. 28 of the dogs in the study were mixed breed, 
and the remaining 72 dogs fell into 28 other breed categories. However, this study was not conducted 
using histopathological analysis; instead, cytopatological analysis was performed with the limitations 
this implies. Compared to histological analysis, the structural architecture of a tissue cannot be 
studied, and sample analysis is limited to cell morphology alone.  
 
The estimated incidence of lymphoma is 13-33/100 000 dogs each year (Sapierzynski et al., 2010). 
This author also refers to three French studies, where a breed predisposition has been reported in dogs 
suffering from lymphoma: the Boxer is overrepresented regarding T-cell lymphoma and German 
Shepherds more often suffer from B-cell lymphoma. There are studies indicating that the incidence 
rate for lymphoma is relatively high, 114/100 000 dog years at risk (Dobson et al., 2002). Boxer, 
Bullmastiff and Bulldog have a higher incidence of lymphoma than other breeds (Edwards et al., 
2003). Airedale terrier, Scottish terrier and Bassett hound have an increased relative risk for 
developing lymphoma, while Pomeranians and Dachshund are considered to be at lower risk 
compared to other breeds (Teske, 1994). Some chemicals used for lawn care may increase the risk of 
lymphoma in dogs, however products used for flea control and tick control are not associated with an 
increased risk (Takashima-Uebelhoer et al., 2012). 
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BACKGROUND 
The concept of tumorigenesis  
Normal cell division is strictly controlled. The event is mediated by a variety of factors acting in 
unison in a process called the cell cycle. A resting cell is set in the G0 phase, or resting phase. 
When a cell prepares for cell division, it enters the cell cycle in the G1 phase, the phase preceding 
replication (G stands for “gap”). This phase is also known as the growth phase, during which proteins 
needed for DNA synthesis are produced. Replication begins in the S phase, and ends when all 
chromosomes have been duplicated. The G2 phase succeeds the S phase, during which additional cell 
growth is promoted. Mitosis follows in the M phase, and is divided into a prophase, metaphase, 
anaphase and telophase. In the prophase, the chromatin becomes condensated and visible and the 
nuclear membrane disintegrates in prometaphase.  This is followed by the metaphase when the 
chromosomes align for division. The anaphase is the stage when chromosomes are separated and the 
telophase is the phase when nuclear membranes are formed in the daughter cells. The process of the 
cell cycle is strictly controlled by molecules such as cyclins and cyclin dependent kinases (CDK), 
which are expressed during specific phases of the cell cycle. After finishing their purpose, the 
molecules are degradated in the proteasome, a process which is ubiquitin dependent. Growth factors 
promote the formation of cyclins, which then bind to CDK and initiate phosphorylation. One 
important check-point is the restriction point in the transition from G1-S. At this point, retinoblastoma 
protein (Rb) is hyperphosphorylated and factor E2F is activated. E2F in turn induces transcription of 
other factors needed for further progression in the cell cycle, such as DNA polymerase and thymidine 
kinase (Berenstein, 2004). The advancement in the cell cycle is inhibited by the retinoblastoma tumor 
suppressor protein (hypophosphorylated retinoblastoma protein) through direct binding of the E2F 
family and activation of other corepressors (MacDonald and Dick, 2012).  
 
 
 
In order for a tumor to form, the cell has to break away from its normal cell cycle control. Subsequent 
recruitment of abilities by the cell to undergo dedifferentiation (anaplasia), become locally invasive or 
even metastasize will lead to a tumorous development known as cancer. Oncogenes are genes which 
promote the formation of tumors. Oncogenes can be mutated, or simply expressed at elevated levels in 
tumor cells. Overexpression may occur secondarily through loss of regulatory activity. Chromosome 
translocation can also result in the activation of oncogenes. Oncogenes form proteins necessary for cell 
division or cell differentiation. Many receptors regulating the activity of growth factors are tyrosine 
kinases, and cancer drugs may target these receptors such as the tyrosine kinase inhibitor mastinib 
(Masivet®) used to treat dogs with mastocytoma. On the other hand, suppressor genes are genes which 
promote tumor growth when their normal function is lost. This is the case for a very famous 
suppressor gene called p53, which in turn activates the p21 pathway. p21 acts as a CDK inhibitor, 
halting the cell in G1 phase (Schmidt et al., 2010).  
M 
G1 S 
G2 
Fig 3. Schematic illustration of the cell cycle. Length of phase intervals may not reflect relapsed 
time of each phase proportionately. 
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The enzymatic function of thymidine kinase 1 
Thymidine kinase (TK) is an enzyme expressed during S-phase of the cell cycle. The enzyme 
regulates the "salvage pathway" synthesis of DNA.  There are two forms of TK; TK1 found in the 
cytoplasm and TK2 in the mitochondria. Previously, thymidine kinase 1 and 2 were thought to be of 
adult and fetal lineage respectively. In a study from 1971, thymidine kinase purified from human adult 
cells was considered more responsive to negative feedback than thymidine kinase from fetal cells. The 
biological behavior of fetal thymidine kinase thus resembled thymidine kinase from tumorous cell 
lines (Taylor et al., 1972). TK1 catalyzes the phosphorylation of thymidine into thymidine 
monophosphate. In this reaction, deoxythymidine (dT) is phosphorylated into deoxythymidine 
monophosphate (dTMP) with adenosine triphosphate (ATP) as the phosphate donor. The reaction can 
be illustrated as follows: 
 
 
 
 
dTMP is further phosphorylated into deoxythymidine triphosphate (dTTP) and can then be used as a 
substrate for the incorporation of pyrimidines in the growing DNA strand (Berenstein, 2004). New 
strands of DNA cannot be formed without the presence of dTTP, and dTTP is crucial for further 
replication and cell division. De novo synthesis of pyrimidines is a process that requires many more 
steps than what is required in DNA synthesis through salvage pathway. Availability of dTTP is the 
rate limiting step in DNA synthesis, and studies have shown that TK1-activity increases in serum in 
conditions such as lymphoma in dogs (von Euler et al., 2009). 
 
Fig 4. Simplified illustration of the de novo synthesis of dTMP 
 
 
The sequence of human and ureaplasma urealyticum TK1 has previously been mapped, and the 
enzyme consists of a tetramer in its native form. Two domains are present: one αβ-domain and one 
zinc finger domain, the active site being situated between the two domains. A lasso-shaped structure 
of 70-88 amino acids makes up the active site. Two β-sheets are joined together via a zinc ion in this 
enzyme. The C-terminus is an ubiquitin ligase site, responsible for the cell cycle dependent 
degradation. Thymidine kinase is 89,3 % homologous between dogs and humans. The first 62 amino 
acids are identical, but the sequences are only 59,5 % identical in the last amino acids. Cellular 
thymidine kinase purified from canine MDCK is mainly active in a dimer or tetramer form. Western 
blot analysis confirmed bands of 26 kDa (compared to 25 kDa for human TK1) corresponding to 
active fractions in the range of 40-100 kDa as determined by radiochemical methods (Sharif et al., 
2012).  
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𝑪𝒂𝒓𝒃𝒂𝒎𝒐𝒚𝒍 𝑷𝒉𝒐𝒔𝒑𝒉𝒂𝒕𝒆+ 𝑨𝒔𝒑𝒂𝒓𝒕𝒂𝒕𝒆
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𝑫𝒊𝒉𝒚𝒅𝒓𝒐𝒐𝒓𝒐𝒕𝒂𝒕𝒆+ 𝑵𝑨𝑫+
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𝑶𝒓𝒐𝒕𝒂𝒕𝒆+ 𝑷𝑹𝑷𝑷
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𝑶𝑴𝑷
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… 
 
 
dT + ATP  dTMP + ADP 
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The role of thymidine kinase in diagnostics  
TK-measurement in serum is available for use in human and veterinary medicine to aid diagnosis, 
prognostics and to predict relapse before the tumor becomes clinically manifest. However, these 
methods have mainly been of use on lymphoma and leukemia patients. TK-measurement can be used 
as a tool to predict the progression from myelodysplastic syndrome (MDS) in acute myeloid leukemia 
(AML) (Musto et al., 1995). In this study, activity of TK1 was measured in serum by a radioenzymatic 
assay. Only a weak relationship could be found between the development of MDS and levels of lactate 
dehydrogenase (LDH). 
 
Different assays are available today for measurement of TK1-concentration in serum. A 
radioenzymatic assay (TK-REA, Prolifigen) is available for use on canine serum samples. An enzyme-
linked immunosorbent assay (ELISA) has also been evaluated and been proven to correlate with 
values obtained by TK-REA (von Euler et al., 2006). Increasing TK-values in serum has been 
correlated with survival time and is indicative of relapse in dogs with lymphoma. A decline is 
observed when CR has been achieved, and values seen in dogs in remission do not differ from those 
obtained in healthy controls (von Euler et al., 2004).  
 
TK LIAISON (DiaSorin) is a non-radiometric immunosorbent assay that uses anti-AZTMP (3´-azido-
deoxythymidine monophosphate) antibodies to measure TK1-activity. With this method, TK activity 
in serum was significantly lower in healthy dogs and dogs with inflammatory conditions, than in dogs 
with malignant lymphoma and leukemia. Activity was also significantly higher in dogs with leukemia 
and lymphoma that were not in remission, compared to dogs that were in remission (von Euler et al., 
2009). A dot-blot enhanced chemiluminescence (ECL) assay has also been tested on patients with 
gastric cancer. A decline in TK1 in serum (parallel to the enzymatic half-life of TK1) could be 
observed in cancer free patients postoperatively, and an increase by 173 % could be observed in 
patients with distant metastasis 35 days postoperatively. In contrast, enzymatic levels were reduced to 
52,3 % in cancer-free individuals, and to 80 % in patients with metastatic disease (Zou et al., 2002). 
The concentration of thymidine kinase determined by measurement by dot blot ECL is a biomarker for 
screening of different types of malignancies, as determined by a Chinese study on 35365 people (Chen 
et al., 2011). This has also been determined in another study, where TK1 levels were related to 
progression of hyperplasia of the breast and prostate, and development of hepatic carcinoma (Huang et 
al., 2011). Measurement of thymidine kinase concentration in serum by ECL dot blot is also related to 
prognosis of patients suffering from non-Hodgkins lymphoma (Pan et al., 2010).  
 
Measurement of TK1 in serum samples from human patients with chronic a lymphocytic leukemia 
(the most common haematological neoplasm of adults in the Western world) also correlates with 
survival and prognosis. Chronic Lymphocytic Leukemia (CCL) carries a variable prognosis, where 
some patients survive long after diagnosis and some patients progress to develop large-cell B-cell 
Lymphoma (Richter's syndrome). TK has been of diagnostic value in determining which patients are 
at risk of progressing to this stage. TK-activity is proportional to another prognostic marker, IGH 
(Immunoglobulin Heavy Chain), for which a mutation rate of > 2 % has been shown to correlate with 
an indolent clinical development. In the study concluding this, TK1 was measured by 
chemiluminescent assay (Konoplev et al., 2010). TK-activity in serum as measured by the 
radioenzymatic Prolifigen assay can be used to assess prognosis independently of other prognostic 
factors in patients with CLL, such as lymph node size and WBC-count in human patients (Hallek et 
al., 1999).   
 
In an English study conducted on 73 dogs with lymphoma treated with chemotherapy (first time 
treatment), TK-levels (i.e. TK1-activity, U/L) fell when remission was achieved. This applied to the 
dogs that had elevated TK-levels at the beginning of treatment (Elliott et al., 2013). There are 
applications in veterinary medicine for measuring TK activity in serum. This is done today at the 
Department of Clinical Chemistry, University of Agricultural Sciences, Uppsala, Sweden. In a study 
covering 20 dogs with lymphoma or leukemia (1 case of acute hematopoietic leukemia), TK activity in 
serum was significantly higher for all dogs. TK activity declined as the tumor burden was reduced 
after chemotherapy in 5 of the dogs (Nakamura et al., 1997).  
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13 dogs were used as a control group and a blood sample was also drawn on 5 dogs with inflammatory 
conditions with resulting non-neoplastic leukocytosis. The TK-activity was slightly increased 
compared to the control group in 2 of these 5 sampled dogs. However, the TK-activity quickly fell in 
line with declining WBC. LDH activity and TK activity correlated with each other. Although the LDH 
activity increases in patients with lymphoma (also shown by Marconato et al., 2010), LDH is not a 
proliferation marker and is also induced in other clinical conditions such as liver disease, myocardial 
lesions and hemolysis (Nakamura et al., 1997).  
 
TK activity can also be used to predict survival in dogs before initiation of treatment. 44 dogs then 
were treated with chemotherapy according to the ADRIA-plus-protocol (doxorubicin based). 50 % 
survival time was 9 months for dogs with TK values < 30 U/L in comparison with 1 month for dogs 
with TK > 30 U/L. The clinical response to treatment was reflected in the TK values and thus, TK-
measurement in serum can be used to monitor the dogs with lymphoma and anticipate relapse before 
the disease becomes clinically evident (von Euler et al., 2004).  
 
Regarding solid tumors, measurements of the TK enzyme has mainly been studied in human patients 
with esophageal, cardial and lung carcinoma (Li et al., 2010), thyroid and gastric carcinoma (Chen et 
al., 2010) and renal cell carcinoma (Luo et al., 2009).  Activity of TK1 in serum is positively 
correlated to number and size of induced colorectal tumors in rats (Kuwa et al., 1996). A study by He 
et al was conducted on material on material from human patients with non-Hodgkins lymphoma, lung 
cancer, esophageal cancer and breast cancer. Serum levels of TK1 as measured by ECL dot blot assay 
were found to correlate with pathological stages and clinical grades in patients with esophageal cancer 
and lung cancer respectively. In the breast cancer group, levels of TK1 in serum were able to predict 
relapse 3 months postoperatively (He et al., 2010). As for those patients with lymphoma, TK1 levels 
were of use in determining 5 year survival before initiation of treatment and 28 days after.  
 
Measurement of TK activity has been used clinically to a greater extent for breast cancer patients than 
for the other above mentioned tumors. Increased activity of TK among breast cancer patients is 
associated with worse prognosis for the patient and poorer survival postoperatively. High TK activity 
also indicates a poorer response to tamoxifen therapy (Foekens et al., 2001).  For breast cancer 
patients, a higher TK1-value in serum as measured by dot blot is related to a 6-7 times higher hazard 
ratio of developing recurrence (Huang et al., 2012). The problem with measurements of TK1-activity 
in serum of dogs as well as people with solid tumors has been that some cancer patients do not exhibit 
elevated TK values compared to healthy individuals (von Euler et al., 2004 and He et al., 2005). It has 
been shown that the level of TK1 in serum does correlate with cellular level of TK1 within patient 
categories as divided by tumor volume, and serum TK1 in turn does correlate with the overall tumor 
burden in a study conducted on 89 human patients with non-Hodgkins lymphoma (Rehn et al., 1995).  
Therefore, other TK assays such as FLT-PET (see next paragraph) can be evaluated in situ and might 
be of better use in reflecting any ongoing mitosis. It has been shown in dogs aswell that S-phase 
activity rates evaluated by DNA-histogram analysis is significantly related to survival in dogs 
suffering from malignant mammary tumors (Hellmén et al., 1993).  
 
TK has been used as a target enzyme in PET-scans in humans. The patient is injected with a substance 
tagged with positron emitting isotopes. In the decay of the isotope, a proton is converted into a 
neutron, a positron and a neutrino. The positron will eventually annihilate with an electron, resulting in 
the formation of photons. The photons are detected in a ring of scintillyzing crystals surrounding the 
patient, and an image is formed (Lawrence et al., 2010). Two substances that have been used 
extensively in PET diagnostics are FDG and FLT. PET scan reflecting the uptake of the positron 
emitting isotope 3´-deoxy-3´ (F18) fluorothymidine (or FLT) is a more specific method for evaluation 
of the proliferative activity in a tumor than the traditionally used (18F)-fluoro-2-deoxy-D-glucose 
(FDG). FDG mirrors glucose uptake. The F-atom at C2 position prevents FDG from being a substrate 
in glycolysis; FDG "gets stuck" intracellularly (Lawrence et al., 2010). Glucose is a substrate in many 
tissues. However FLT (substrate for TK) is more specific marker of proliferation (Kenny et al., 2005). 
FLT is accumulated in primary tumors, lymph nodes and lung metastases of breast cancer patients. 
The accumulation of FLT is heterogeneous in both primary tumors that metastasis of breast cancer 
patients, reflecting an uneven distribution of cells in mitosis. The delivery and retention of FLT is 
higher in cancer tissue than in normal tissue.  
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Retention of FLT in breast tissues correlates with the proliferation marker Ki67, indicating that 
retention of FLT is correlated to increased proliferation. Retention of FLT stands in relation to the 
conversion of FLT to FLT-phosphate by TK1 (Kenny et al., 2005). PET/CT examinations are 
increasing in veterinary medicine, but it has not been used extensively due to the cost of the analysis. 
CT mirrors the anatomical image, while a PET scan shows the metabolic profile. PET therefore has a 
potential area of use to more quickly find malignant processes. However, there is a need for closer 
study of FLT uptake in animals. FLT uptake is affected by chemotherapy in humans. Doxorubicin 
reduces absorption of FLT, while 5-fluorouracil, gemcitabine increases absorption of FLT (Lawrence 
et al., 2010). Because the distribution, uptake and metabolism of FLT are less optimal than for FDG, 
FDG is still used in tumor diagnostics to a great extent. The uptake of FLT is generally lower than the 
uptake of FDG. FLT has a potential area of use as an indicator of how the tumor will respond to 
treatment (Herrmann et al., 2007). A lower uptake of FLT in a tumor after indicates a positive 
response to the therapy and improved survival. PET-scan, however, is very expensive and is not 
readily accessible to canine patients as of date.  
 
AIM AND HYPOTHESIS 
Immunohistochemical methods have become routine in the diagnostics of tumors. Receptors that have 
been reported to be of importance for the development of mammary tumors are for example the 
receptors for estrogen and progesterone (ER/PR), BRCA1, p53, E-cadherin and HER2/neu and mitosis 
markers such as Ki67, AgNOR and PCNA (more on the pathogenesis can be read in “Appendix I”). 
As described in the “Background” section, analysis of thymidine kinase in serum samples has its 
limitations due to the heterogenecity of the activity of thymidine kinase in patients suffering from 
solid tumors compared to hematological malignancies. PET-scans are expensive and not widely used 
in clinical veterinary practice. However, it is common to evaluate neoplastic conditions through 
biopsies or extirpated tissue after surgery. Histological evaluation is the golden standard in oncological 
diagnostics in veterinary medicine today. Tissue specimens are most commonly fixed in formalin, 
although other modes of fixation are available. For these reasons, it is relevant to examine whether the 
detection of TK1 in tissue samples could potentially be used to assess tissue samples from dogs with 
neoplasia. Mammary tumors and lymphomas were chosen as models due to the widespread occurrence 
of these conditions in the canine population. Furthermore, these conditions are widespread among the 
human population as well, and studies on canines are therefore of comparative value. The purpose of 
this study is to act as a pilot in assessing the methodology for immunohistochemical detection of 
thymidine kinase in tissue samples from dogs. TK1 is an S-phase-specific enzyme, and therefore 
reflects active cell division. Such a marker is therefore potentially useful in cancer diagnostics as a 
complement to traditional histological assessment. If the expression of thymidine kinase is 
characterized, the method could have potential use in routine clinical pathology. Analysis of samples 
obtained from mastectomies could serve as a useful tool in determining the prognosis and treatment 
result after surgery of patients with mammary tumors. Immunohistochemical detection of thymidine 
kinase could serve as a marker in determining if surgical margins are sufficient, and if additional 
chemotherapy will be necessary. It could also have potential use in the establishment of minimal 
residual disease (MRD) after chemotherapy treatment. The current questions for this study are as 
follows:  
 
• Can TK1 be detected in tissue samples from dogs using the chosen method?  
• Is TK1 expressed in mammary tumors and lymphoma from dogs, and if yes, to an equal 
extent? 
• Is there any difference between malignant and benign mammary tumors or B-and T-cell 
lymphoma in their expressions of TK1? 
• Is there a difference in TK1 expression in neoplastic tissue compared to non-neoplastic tissue? 
• Is the expression of TK1 related to the mitotic index? 
 
The hypothesis is that the expression of TK1 will increase with increasing levels of mitotic activity 
(and malignancy in mammary tumors, since mitotic activity is a criterion in assessment of 
malignancy). Moreover, the expression of thymidine kinase will be evident to some extent in all of the 
lymphoma samples (and more apparent in T-cell lymphomas). The expression of thymidine kinase 
would also be positively correlated to the mitotic index.  
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MATERIALS AND METHODS 
Tissue samples, previously fixed in formalin and embedded in paraffin, were retrieved at the archive 
of the Institution of Pathology and Wildlife Disease at the National Veterinary Institute, Uppsala, 
Sweden. 23 mammary tumors from 12 dogs and 16 lymphoma samples were originally included in the 
study. Out of those 23 tumor samples, 3 had to be excluded due to excessive cartilage formation. All 
of the mammary tumors were originally biopsy specimens sent to the National Veterinary Institute 
between the years 2010-2012. 3 of the lymphoma cases were necropsy specimens, the other were 
biopsy specimens sent in between 2010-2012. Samples of normal mammary tissue (3 samples) and 
normal lymph nodes (4 samples) were collected at necropsy at the Institution of Pathology, Swedish 
University of Agricultural Sciences. Samples were analyzed according to the method described below.   
 
Paraffin embedded tissue samples were cut into 2-3 µm thick sections and deparaffinized in xylene,    
2 x 10 minutes. Tissue sections where then passed through declining concentrations of ethanol: 99,5 % 
ethanol, 2 x 5 min, 95 % ethanol 1 x 5 min, 70 % ethanol, 1 x 5 min and finally distilled water 5 
minutes. The sections were washed with TBS (Tris-Buffered Saline, 0.05 M, pH 7.6) in 5 minutes and 
incubated in Target Retrieval Solution in a microwave oven, 750 W, 8 min and 350 W, 14 minutes in 
order to break the protein – aldehyde bonds. Sections were cooled off in 20 minutes at room 
temperature, rinsed in tap water for 20 minutes and washed in the TBS buffer in 5 minutes. To block 
endogenous peroxidase, the samples were incubated in 0,3 % H2O2 diluted in TBS for 30 minutes, 
after which the sections were washed with TBS-buffer in 5 minutes. The sections were incubated in 2 
% BSA (Bovine Serum Albumin) for 30 minutes in room temperature in a humidity chamber in order 
to block nonspecific binding sites. After this step, the sections were incubated with the primary 
antibody (XPA-161, clone 528-2, AroCell) diluted 1: 200 in 1 % BSA, and incubated in a humidity 
chamber at room temperature for 2 hours. Sections were then washed for 7 minutes in TBS after 
incubation. LSAB (labeled streptavidin-biotin system, Dako) was used for immunohistochemical 
detection. The sections were washed again in TBS-buffer for 5 minutes and then incubated in DAB 
(3,3´-diaminobenzidine) solution for 7 minutes (DAB solution consisted of 2 ml of DAB, 38 ml of 
TBS and 40 µl of H2O2 added as a catalyst). The sections were washed in tap water for 5 minutes, 
stained with Mayer's hematoxylin for no more than 2 minutes and then rinsed again in tap water until 
blue. Sections were passed through 95 % ethanol for 2 x 1 minute, 99,5 % ethanol in 2 x 1 minute and 
xylene in 2 x 10 minutes and mounted with Pertex. All samples were and examined using light 
microscopy (Zeiss 25 Standard). Tissue samples stained with hematoxylin – eosin were 
simultaneously examined to determine degree of malignancy and tumorous spread in the samples. 
Mammary tumors were divided into subtypes according to the WHO-classification system described 
by Misdorp et al, 1999 with proposed amendments by Goldschmidt et al from 2011. Lymphomas not 
previously immunophenotyped were immunohistochemically stained with an anti-CD79α antibody 
and a CD3-antibody to determine whether the tumor was of B-cell (positive to CD79α) or T-cell 
(positive to CD3) lineage.  
 
Level of thymidine kinase expression was determined by examining 10 HPFs (40X). 100 cells in each 
HPF were counted and assessed regarding positivity for TK1. Results were added and divided by 10 to 
render a mean positive percentage of cells in the sample. Mitotic index was evaluated for the 
lymphoma samples by counting the number of cells in mitosis in 10 HPFs (40X). Mitotic index was 
plotted against expression of TK1 to determine if a correlation between the parameters could be 
established using the SDSS statistics program from IBM.  
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RESULTS 
Mammary tumors 
The distribution of breeds, ages and tumor types in the mammary tumor group is listed in table 1. 
Some dogs had multiple histological diagnoses, each diagnosis representing one sample. Age 
distribution was between 4-11 at time of diagnosis, with a mean age of 8,2 years. Two of the dogs 
(16,7%) were of mixed breed, the rest of the dogs were of eight different breeds.  
 
Table 1. List of mammary tumors assessed in this study 
Breed Age Diagnosis 
Mixed Breed 10 Benign mixed tumor, complex 
carcinoma 
Mixed Breed  8 Benign mixed tumor, complex 
carcinoma 
German Shepherd 9 Tubular carcinoma, simple type 
Papillion 10 Tubular carcinoma, simple 
type; solid carcinoma 
German Shepherd 6 Benign mixed tumor, adenoma, 
simple type; complex 
carcinoma 
Poodle 8 Benign mixed tumor, tubular 
carcinoma, simple type 
Irish Setter 4 Benign mixed tumor, carcinoma 
complex 
Irish Setter 8 Benign mixed tumor, complex 
carcinoma 
Bichon Havanais 8 Complex carcinoma 
Afghan Dog 11 Complex carcinoma 
Poodle Unknown Tubular carcinoma, simple type 
Schnauzer 8 Adenoma, simple type 
 
Table 2. Distribution of mammary tumor samples 
 Frequency Percent 
Adenoma, simple type 2 10 % 
Benign mixed tumor 6 30 % 
Complex carcinoma 7 35 % 
Solid carcinoma 1 5 % 
Tubular carcinoma, simple type 4 20 % 
 
Due to excessive background staining and inadequate signal intensity in the epithelial components, 
samples could not be assessed immunohistochemically regarding TK1. The staining was too weak to 
be rendered positive, and the staining intensity was not stronger than that found in normal mammary 
epithelium.  Normal mammary tissue samples came from one Dachshund (8 years), one Rottweiler (6 
years), and one Bassett Griffon de Verden (8 years).  
 
 
Thymidine kinase expression was found in capsular lymphocytic infiltrations in two of the samples. 
No statistically significant difference was found in normal samples compared to mammary tumors, 
since normal mammary gland epithelium expressed the same signal intensity and level of background 
staining.  
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Lymphomas 
17 cases of lymphoma were examined. 3 cases were necropsy cases (17,6 %), the rest were biopsy 
specimens. Out of the 17 cases included in the study, 9 (53%) were of B-cell lineage and 8 (47 %) 
were of T-cell lineage. Ages of the dogs included in the study varied between 1-14 years, with a mean 
age of 7,6 years (dates of birth not known in the majority of the cases). One dog (5,9 %) was of mixed 
breed, for two of the dogs (11,8 %) the breed was not known, and the rest of the dogs came from ten 
different breeds. The expression of thymidine kinase in lymphoma samples is listed in table 6.  
 
Table 3. Specification of breeds, ages and expression of thymidine kinase 1 in lymphoma samples 
Breed Age Localization Type Biopsy/Necr
opsy 
specimen 
Mitotic 
index 
TK1-
expression 
(mean % of 
tissue) 
Bassett Hound 7 Lymph node B B 16 1,6 % 
Rottweiler 8 Spleen B B 11 0,8 % 
Golden 
Retriever 
8 Spleen B N 4 0,4 % 
Jack Russell 
Terrier 
11 Lymph node B B 35 0 % 
Nova Scotia 
Duck Tolling 
Retriever 
4 Lymph node B B 12 2,6 % 
Unknown 8 Subcutaneous B B 5 0,1 % 
Rottweiler 5 Lymph node B B 17 0 % 
Dachshund 9 Subcutaneous B B 3 1,7 % 
Golden 
Retriever 
8 Lymph node B B 2 0 % 
Mixed Breed 7 Skin T B 12 2,9 % 
Dachshund 1 Lymph node T B 2 0 % 
Cavalier King 
Charles Spaniel 
8 Skin T N 19 0 % 
Unknown 8 Skin T B 13 14,9 % 
Finnish Sptiz 10 Spleen T B 4 0,7 % 
Flat Coated 
Retriever 
Unknown Alimentary T N 1 0 % 
West Highland 
White Terrier 
14 Skin T B 5 26,1 % 
German 
Shepherd 
5 Oral mucosa T B 6 0 % 
 
4 samples from animals suffering from non-neoplastic conditions were also examined. All of these 
samples were collected at necropsy. Originally, 5 samples were collected but one lymph node was 
excluded due to fatty involution of the parenchyma. All of the animals showed low degree of 
decomposition. 
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Table 4. Expression of thymidine kinase in normal lymph nodes 
Breed Age Cause of death Expression of thymidine 
kinase 1 (mean % of tissue) 
Rottweiler 6 years Epilepsy 1,4 % 
Samoyed 2 months Aortic stenosis 0 % 
Pug 9 years Myelodegenerative disorder 2,6 % 
Whippet 7 years Traumatic injury to spine 1,1 % 
 
Differences in mean thymidine kinase expression could not be statistically assessed due to a low 
number of samples. A mean percentage of cells expressing thymidine kinase expression could not be 
calculated due to inadequate amount of samples and wide range in thymidine kinase expression. A 
median value was calculated as a comparison. Cells showed strong staining intensity for thymidine 
kinase.  
 
Table 5. Comparison of TK1 expression in B-cell lymphomas, T-cell lymphomas and normal lymph 
nodes 
 Median thymidine kinase 
expression (% of tissue) 
Range 
B-cell lymphomas 0,8 % 0-26,1 % 
T-cell lymphomas 1,8 % 0-2,6 % 
Normal lymph nodes 1,3 % 0-2,6 % 
 
Expression of thymidine kinase was not correlated to mitotic index.  
 
Fig 5 (left) and 6 (right). Cells strongly positive to TK1 in a normal lymph node (fig 5) and in a T-cell 
lymphoma of the skin (fig 6), 50X. 
 
Lymphatic tissue from animals suffering from neoplasia 
Two lymph nodes from animals suffering from complex carcinoma (2) and lymphoma (1) without 
metastatic involvement were also examined. These lymph nodes expressed a high percentage of TK1 
when compared to other samples. Median percentage of thymidine kinase expression was 3%. 
 
Table 6. Expression of thymidine kinase 1 in lymph nodes from animals suffering from neoplastic 
disease without metastatic involvement 
Breed Age Diagnosis Expression of thymidine 
kinase 1 (mean % of tissue) 
German Shepherd 6 Complex carcinoma 3 % 
German Shepherd Unknown Complex carcinoma 0,4 % 
Flatcoated Retriever Unknown Alimentary T-cell 
lymphoma 
6 % 
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DISCUSSION 
A statistically significant increase in the expression of thymidine kinase compared to normal tissue 
samples could not be determined in this study. The following discussion will regard possible causes 
for this, and improvement for future studies.  
 
Preparation of samples 
According to the records, 3 out of 17 cases of lymphoma were necropsy cases. As for the normal 
tissue samples, sampling was performed at necropsy. This has implications on morphological aspects 
of the tissue due to cadaverous change. Lymph node tissue samples in the “normal” group were taken 
directly from the site of necropsy into formalin. However, necropsy did not occur until the next day 
and cadaverous change was 1 on a scale from 0-3. 0 represents a specimen that has gone directly from 
euthanasia, and 3 represents significant cadaverous change. In the lymphoma group, cadaverous 
change was 3 for all specimens. This may have had an effect on the outcome of this study, since the 
cadaverous change in an organ can cause autolysis of cells, denaturation of proteins and further 
deteriorate the possibility of an accurate interpretation. Moreover, B-cells have been shown to undergo 
autolysis much faster than any other immunological cell, and within 3 days the cellular membranes 
disintegrate. Necrotic samples will appear amorphous, and intercellular boundaries will be hard, if not 
impossible, to distinguish. Even though the majority of the samples were originally biopsy specimens 
according to records, they could have been the subject of morphologic deterioration if they were not 
immediately quenched in formalin after sampling. This can lead to dehydration of the sample. 
Unfortunately, there were no means to control the sampling in this study since archived material was 
used. This bias has to be taken into account when samples are assessed. It is also important to ensure 
that the samples are quenched in adequate amounts of formalin (v/v ratio 90 % formalin and 10 % 
tissue). We can view an example of inadequate fixation here.  
 
Fig 7. Inadequate fixation after sampling gives this specimen a stripy and washed-out appearance. 
This specimen is a B-cell lymphoma from a lymph node, hematoxylin – eosin stain, 10X.  
 
 
 
However, formalin pigments may form if tissues are left in formalin for too long. All types of 
pigments may affect interpretation of results. There are other fixatives described, which may preserve 
the morphology of tissue specimens even more than formalin. One example is RCL-2, which has been 
described to be of use regarding immunohistochemistry with comparable results on detection of the 
estrogen- and progesterone receptor in breast tumor samples (Delfour et al., 2006). One benefit of 
RCL-2, is the preservation of DNA integrity. However, formalin is the fixative of use in clinical 
veterinary medicine today. The reason archived and necropsy material was utilized in this study was 
due to its availability. This also implicated that procedures on live animals could be avoided for the 
purpose of the study and archived material was used in its place.  
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However, fresh biopsy specimens are preferable and it would be advisable to consider fresh biopsy 
specimens or cell cultures to be used for future assessment of this method. If live animals are used, it 
will also make it possible to draw blood samples for analysis of the activity of thymidine kinase in 
serum.  
 
Morphological aspects 
Morphology is a key element when it comes to interpretation of results. Problems arose with 3 of the 
mammary tumors, which simply slided of the glass during preparation. This applied to benign mixed 
tumors and tumors involving thin strips of skin and/or connective tissue, as can be found in the udder. 
Presence of cartilage in the samples made them slide of even more efficiently. In order to make the 
samples stick the samples to the glass, samples were placed in 60oC for 10 minutes before they were 
placed in the first bath of xylene. Problems occurred after treatment in the microwave and 
simultaneous incubation with Target Retrieval Buffer. The Target Retrieval Buffer itself has a pH 
value of 6, compared to the Target Retrieval Buffer with pH 9 which is also available. The buffer is a 
weak citric acid solution and should not affect the morphology to a great extent. Previous studies on 
the expression of the androgen receptor has proven the method of antigen retrieval with citrate buffer 
(pH 6) and microwave pretreatment to be superior to enzymatic treatment with pepsin or trypsin 
followed by pronase (Shi et al., 1993). The heat provided by the microwave is necessary to break the 
formalin induced protein-aldehyde bond. If this step is not done, then the tissue is still fixed and 
cannot be analyzed immunohistochemically. The water bath itself is very gentle, and samples were not 
placed directly under the faucet. To block endogenous peroxidase in the tissues, samples were 
incubated with methanol and hydrogen peroxide in a 0,3 % solution initially. However, the methanol 
was found to deteriorate morphology, and was therefore replaced by TBS for dilution of the 30 % 
hydrogen peroxide. Alcohol can also have a negative effect on morphology if samples are left to 
rehydrate for too long. However, it is important that the first steps in xylene and ethanol is properly 
done, otherwise samples will be rendered impossible to analyze due to the fact that the aqueous 
solutions used will not be able to penetrate the tissues since the presence of paraffin makes it 
hydrophobic.  
 
In human medicine, freeze sections often replace formalin fixed sections. However, this is mainly used 
in human medicine intraoperatively. In freeze section preparation, acetone often replaces the use of 
alcoholic substances in preparation procedures and the Envision system has been implemented on use 
on freeze sections. Envision is also horse-raddish peroxidase based, with a dextran coupling for 
increased sensitivity (Kämmerer et al., 2001). In human medicine, freeze sections have been proven 
superior to touch imprints in detecting macro- and micrometastases intraoperatively in axillary lymph 
nodes of patients with breast cancer (Krishnamurty et al., 2009). The implementation of freeze 
sections in every-day diagnostics is not yet practiced in veterinary medicine and fixation in formalin is 
the “golden standard” in sample preparation for histological analysis. For this reason, it is advisable to 
continue developing the method on paraffinized material, since this is of greatest value to veterinary 
clinical pathology.  
 
The antibody 
Different antibodies and assays have been designed to detect TK1 in serum. These antibodies have 
been of monoclonal and polyclonal nature. One of those antibodies is XPA 210, which has been 
designated its name from the central amino acid sequence in the epitope 
(eXposedProliferationAntigen210). XPA210 has been shown to efficiently detect the presence of 
thymidine kinase in samples of renal carcinoma from human patients (Kruck et al., 2012).  In the 
referred study, there was a significant difference between samples with renal cell carcinoma and 
normal tissue (more on this is the section “A comparison to previous studies”). Trials have been made 
to produce polyclonal antibodies from rabbits, one of those antibodies having the ability to bind to 
recombinant canine TK1 as well as human TK1, with a 7 amino acid epitope between position 196 and 
223 (Nyberg, 2007). It has been shown that intact TK1 is poorly immunogenic, and therefore 
immunization with peptide fragments has been necessary in order to produce antibodies against TK1.  
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The antibody used in this study is XPA161. A 23 peptide sequence corresponding to the lasso domain 
makes up XPA161 (SEQID01). The antibodiy XPA161 can be crosslinked to bovine serum albumin. 
The peptide is made by crosslinking by NeoMPS Inc in San Diego, producing a peptide of >96% 
purity consisting of amino acid sequence 161 to 183 of human TK1 (amino acid sequence 
AYTKRLGTEKEVEVIGGAD KYHS-NH2). The XPA161 antibody is manufactured according to the 
following procedure:  
 
A cysteine residue is added to the N-terminus and a suspension is made with 100 µg peptide, 500 µg 
PBS pH 7,2 and mixed with equal amount of Freuds incomplete adjuvans. The antibody XPA161 is 
produced through immunization of female Blab/c mice, injected subcutaneously with the above-
mentioned mixture and then reinjected at 2,4 and 6 weeks with boosters of 50-100 µg of antigen and 
Freuds incomplete adjuvans. Splenocytes are harvested from the mice and mixed with mouse 
myeloma cells SP2/0. Appropriate cell lines are selected through ELISA-analysis of cell cultures. The 
selected cells where cloned 3-4 cycles. Using the ELISA-method, the cell cultures with the highest 
amount purified antibody were selected, lyophilized and suspended in buffer (Gasparri et al., 2010).  
 
Immunohistochemical trials of the antibody have been performed on human tonsils and lymph node 
near a cancerous bladder. It has been shown that the antibodies XPA161 and XPA210 react with the 
same cells as Ki67/MIB-1-antibodies, although MIB-1-antibodies also show reactivity in the nucleus. 
The study included in the patent document EP 2164954 A2 used an avidin-biotin-peroxidase system 
(ABC) and the DAB chromogen. Dot blot assays have also been performed using the XPA161 as well 
as XPA210 on breast cancer samples and lung cancer samples from humans. XPA161 seems to react 
more with recombinant TK1 than wild type TK1. However XPA210 reacts similarly with both kinds 
of TK1. XPA210 is produced in a similar fashion to XPA161. However, to produce this antibody, 
American egg-laying hens are immunized intramuscularly and eggs harvested. The epitope used is the 
human amino acid sequence no 195-225 (GQPAGPDNKENCPVPGKPGEAVAARKLFAPQ-OH).  
 
The canine TK1 protein is a 242 amino acid protein (human TK1 is 234 amino acids long) according 
to the NCBI protein database. Searches were made using the queries “thymidine kinase” and “homo 
sapiens” or “canis lupus familiaris”. The sequence of the canine equivalent is a predicted sequence 
according to the gene found in locus XP_003639284. The sequences are listed below, the red sequence 
being the canine version of the enzyme and the black sequence representing human TK1. Differing 
amino acids are highlighted in yellow and zinc-binding domains highlighted in red (adapted from 
Sharif et al., 2012): 
 
MSCINLPTVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC LVIKYAKDTR 60  
MSCINLPTVL PGSPSKTRGQ IQVILGPMFS GKSTELMRRV RRFQIAQYKC LVIKYAKDTR 60 
 
YSNSFSTHDR NTMEALPACL LRDVAQEALG VAVIGIDEGQ FFPDIVEFSE TMANAGKTVI 120 
YSSSFCTHDR NTMEALPACL LRDVAQEALG VAVIGIDEGQ FFPDIMEFCE AMANAGKTVI 120 
 
VAALDGTFQR KAFGTILNLV PLAESVVKLT AVCMECFREA AYTKRLGSEK EVEVIGGADK 180 
VAALDGTFQR KPFGAILNLV PLAESVVKLT AVCMECFREA AYTKRLGTEK EVEVIGGADK 180 
 
YHSVCRLCYF KKASGPPMGL DSRENKENVL VLVPGKPGEG KEATGVRKLF APQHVLQCSP 240 
YHSVCRLCYF KKASGQPAGP DNKEN‒‒‒‒‒    CPVPGKPGE‒   ‒‒AVAARKLF  APQQILQCSP 240 
 
AN 242 
AN 232 
 
Human TK1 has 11 cysteine residues in total, compared to 8 cysteine residues in canine TK1. 
However, 4 of these interact with zinc, rendering 7 and 4 free thiol groups respectively. The 
consequence of this may be formation of oligomers in wild type thymidine kinase, with the possibility 
of 3 more disulfide bonds in the human version of the enzyme (Sharif et al., 2012). This may affect 
antibody sensitivity through different exposure of epitopes.  
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The predicted sequences of XPA161 in the dog and the human are:  
 
Canine XPA161: YTKRLGSEK EVEVIGGADK YHS 
Human XPA161: YTKRLGTEK EVEVIGGADK YHS 
 
The presence of an S instead of T in position 167 of the enzyme could mean that the antibody XPA161 
might not bind as efficiently to canine TK1 as human TK1. On the other hand, it is merely a 
conservative substitution from a serine to a threonine residue and should not affect sensitivity to a 
great extent. However, in the case of the sequence denoted XPA210 (defined as amino acid no 195-
225), the sequences are not identical:   
 
Canine XPA210: GPPMGL DSRENKENVL VLVPGKPGEG KEATG 
Human XPA210: GQPAGP DNKENCPVPG KPGEAVAARK LFAPQ 
 
For future trials, it would be advisable to try another antibody, for example a tailor made antibody of 
the XPA210 canine sequence. In order for an antibody to bind, the antigen must be exposed and this 
sequence must be readily accessible in the folded thymidine kinase protein in vivo. Perhaps it would 
be advisable to characterize wild type thymidine kinase in tumor samples, to determine if this 
sequence is expressed as expected. Any mutations or conformational changes to the protein could 
significantly deteriorate the sensitivity of this method. 
 
Distribution of TK1 in tissue samples and assessment of TK1 expression 
One observation made in this study with regards to the expression of TK1, was that it was highly 
heterogenous. This implies that the method might be less suitable for cytology. In cytology specimens, 
the architecture cannot be examined, and there is a possibility that one might accidentally miss the area 
where TK1-activity is the highest, rendering a false negative result. Even if a neoplastic tissue is 
sampled through biopsy, there is a possibility that the area with the highest TK1-activity is missed in 
the sampling process. Generally, TK1 activity is highest in the periphery of the tumor, and the center 
is often subjected to vast necrosis due to lack of blood supply. The heterogenous expression made the 
assessment of the samples more uncertain. Moreover, assessment of the mitotic index is also a source 
of bias, since mitotic activity may vary greatly even between lymphoma subtypes. This has also been 
described in previous studies (Sokolowska et al., 2012).  
 
10 HPFs where examined and a mean value of expression was calculated. The fact that TK1-
expressing cells seem to muster meant that some of the HPFs had no expression of TK1.  The uneven 
distribution of TK1-expressing cell may render a misleading result. However, the dispersion of TK1-
expressing cells may reveal the actual growth pattern of the tumor, and may still be of value in clinical 
pathology. This fact has to be taken into account in assessment of the samples.  
 
The degree of staining with Mayer´s hematoxylin is also a matter of subjectivity: overstaining a 
sample might overshadow a weak expression of TK1, and too weak staining renders too much 
background. However, the cells showing expression of TK1 were strongly positive, and the dilution of 
the antibody could possibly be increased for lymphoma samples. Inadequate washing of samples and 
replacement of fluids used in the laboratory is also a source of bias. In this study, samples were stained 
in Mayer´s hematoxylin for a maximum of 1-2 minutes, and assessed with regards to degree of 
staining by microscopically during the process. Lymphatic tissue and mammary glands stain easily, 
and it might be necessary to work out a more standardized protocol for how long a section of 2-3 µm 
should be left in Mayer´s hematoxylin for the purpose in question.  
 
Some of the samples showed strong expression of thymidine kinase. This became clear when 
examining samples from dogs with epitheliptropic (T-cell) lymphoma in particular. This is interesting, 
since other T-cell lymphomas were negative for thymidine kinase. T-cell lymphomas are a 
heterogenous group of tumors, and express different biological behavior as seen in this study. 
However, there was a tendency that T-cell lymphomas showed stronger expression than B-cell 
lymphomas, and this is of interest since patients with T-cell lymphomas often have lower activity of 
TK1 in serum (Elliott et al., 2013).  
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One challenge is to quantify the expression of thymidine kinase when the barrier of skin has been 
invaded with neoplastic cells. When this occurs, particularly in conjunction with granulocytic 
inflammation, quantification of the expression in the samples becomes uncertain. However, this is 
indicative of an active lesion, and is not seen in normal skin samples. Before this method can be used 
clinically, it is vital to establish significant cut-off values, and to assess samples that are merely subject 
of inflammation, not neoplasia. In this pilot study, a simple approach was chosen to examine the 
samples. 10 HPFs where examined, and a mean value of TK1-expression was calculated. This might 
not be the best choice for analysis, because of the effect of the method morphologically on skin 
specimens in conjuncting with the uneven occurrence of neoplastic cells, particularly in cutaneous 
lymphoma. Moreover, neoplastic cells invade the skin in epitheliotropic lymphoma, as seen in one 
case in this study. It is important to note that necrotic debris can drastically make the distinction of 
cellular borders more difficult, and may also cause “leakage” of TK1 in the sample with additional 
background as a result.  
 
Fig 8 and 9. Hematoxylin – eosin and TK1-stain (20X) of an epitheliotropic T-cell lymphoma. 
Neoplastic cells have broken through the epithelium and are strongly positive for TK1. 
  
In this study, samples were assessed manually. For future studies, an automatic cell count might 
reduce the level of subjectivity. In immunohistochemical analysis of the estrogen receptor (ER), 
staining intensity and proportion of stained tissue is taken into account according to the Allred scoring 
system. A similar approach might be applicable to immunohistochemical analysis of thymidine kinase. 
However, the level of subjectivity is too high regarding manual reading at this point due to low 
staining intensity in mammary tissue. One important observation was the strong expression of TK1 in 
non-neoplastic samples taken from dogs suffering from known neoplastic conditions (two lymph 
nodes from dogs with mammary tumors and one sample from a regional lymph node from a dog with 
alimentary lymphoma). Those lymph nodes also expressed thymidine kinase, to a much higher extent 
than the primary tumors. This may indicate that the method could indicate cellular activity even when 
micrometastases are not evident morphologically. 
 
One aspect worth noting is the occasional presence of nuclear staining. This was occasionally 
observed in non-neoplastic lymphatic tissue from patients with neoplasia (fig 10), and in tissue 
samples of normal lymphatic tissue from patients not suffering from neoplasia (fig 11). Nuclear 
thymidine kinase may reflect non-specific binding sites, or the presence of actual thymidine kinase in 
the nucleus. If the nuclear binding is specific, the presence of thymidine kinase in the nucleus might be 
an early indication of malignant progression. It is particularly interesting since nuclear staining was 
most prevalent in tissues deemed unaffected by neoplastic transformation. Further studies are 
necessary in order for this to be established. This may play a part in future clinical use of thymidine 
kinase in detecting minimal residual disease (MRD) after treatment with cytostatic agents.  
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Presence of nuclear thymidine kinase has also been observed in other studies. Nuclear staining has 
occurred in other studies using the XPA-210 antibody. Nuclear staining was observed in cases of clear 
cell renal carcinoma, and the authors concluded that this could be due to a lower epitope specificity of 
the XPA210 antibody (Kruck et al., 2012). According to Brockenbrough et al, cytoplasmic staining 
was found to be positively correlated with nuclear staining, and the expression of TK1 was positively 
correlated to Ki67 labelling index in patients with non-small cell lung carcinoma (Brockenbrough et 
al., 2009). In a recent study on human cervical neoplasia, tissue samples were assessed using 
immunohistochemical detection of thymidine kinase 1. The XPA-210 was used in this study as well. 
216 cases of cervical intraepithelial neoplasia (CIN) and 84 cases of invasive cervical carcinoma were 
assessed. The study concluded that TK1 was expressed in the cytoplasm alone, or in the nucleus and 
the cytoplasm simultaneously. Staining for Ki67 was found exclusively in the nucleus. Labelling index 
for total TK1 (cytoplasmic and nuclear) increased with advancing stage in tissue samples from patients 
with CIN. The ratio between the nuclear and cytoplasmic TK1 expression increased for patients with 
CIN from stages I to III. Interestingly, the ratio did not appear to increase further for patients with 
invasive cervical carcinoma stages II-III. TK1 labeling index was significantly correlated to 5 year 
survival for patients with invasive cervical carcinoma. This applied especially to the expression of 
nuclear TK1. Moreover, expression of nuclear TK1 was an independent prognostic factor for patients 
with invasive carcinoma alone or CIN/invasive carcinoma. Nuclear TK1 could help identify patients 
with better survival rates, which cannot be achieved by staining for Ki67 (Chen et al., 2013). 
 
Fig 10 (left) and 11 (right), 50X. Staining for TK1 in a lymph node from a dog with lymphoma where 
the lymph node in question was not deemed affected by microscopy (left). Note the positive staining 
and also occasional nuclear staning. The right figure is of an architecturally normal lymph node, 
where positivity for TK1 was also found in the nucleus.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alternatives approaches to detection with LSAB 
In our samples, we detected a high degree of non-specific background staining. This can be attributed 
to either the antibody or the system used. Switching from LSAB to an ABC based system would 
probably not solve this issue since avidin, in constrast to streptavidin, is not isoelectrically neutral to 
tissue and might also bind to carboxylic acid groups (Diamandis and Christopoulos, 1991). The 
Envision system (Dako) is also a peroxidase based system, but is bound to a dextran backbone for 
increased sensitivity. The backbone can hold up to 100 enzyme molecules and 20 antibodies per 
backbone (Ramos-Vara and Miller, 2006). In comparison to LSAB, Envision does not implement the 
use of avidin-biotin, which may decrease level of background staining according to some studies 
(Ramos-Vara and Miller, 2006). However, the Envision system still implements detection with 
peroxidase, a substance which is apparently abundant in mammary tissue (see fig 15). The Envision 
system has been developed for use with antibodies derived from mouse, and could therefore be used 
with XPA161. The LSAB system is developed for use with antibodies from mouse, rabbit and goat 
according to the manufacturer. In this study, staining of positive cells was often very obvious and 
signal intensity in lymphoma samples was deemed satisfactory.  
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Another way to increase signal intensity in mammary tumor samples could be to decrease the degree 
of dilution of the primary antibody, or include the addition of biotinyl tyramide. According to one 
study, the addition of biotinyl tyramide may increase signal intensity by up to 10-100 times. However, 
the result obtained does depend largely on the primary antibody (Hunyady et al., 1996).  
 
Due to high degree of background staining, an alkaline phosphatase based system might be better 
suited for this type of immunohistochemistry. This system is not routinely implemented in diagnostics 
at the National Veterinary Institute in Sweden today. Endogenous alkaline phosphatase is susceptible 
to blocking by levamisole (Cordell et al., 1984), while calf intestinal alkaline phosphatase is not. The 
presence of endogenous peroxide and biotin may be a disturbing element in the interpretation of 
samples, and may be blocked by sodium azide in addition to H2O2 (Malorny et al., 1988), and 
commercially available avidin-biotin blocking kits. One might also consider coating samples in avidin 
and biotin to rid samples of excess binding sites. Quenching samples in eggwhite, sodium azide and 
bovine serum albumin as a source of avidin and subsequent coating with skimmed milk as source of 
biotin has also been described as a blocking method (Miller et al., 1999).  In some of the samples, 
background staining was present in the positive controls but not the negative controls. This can be 
attributed to properties in the antibody or dehydration of specific samples, especially around the edges 
of the sections during preparation.  
 
A comparison to previous studies 
Although it has not been confirmed in this study, immunohistochemical studies on human tissue have 
shown that the expression of TK1 in the tissue of breast cancer patients is significantly higher than in 
normal breast tissue. Tissue histologically classified as normal may stain positively for TK1. This 
happens in up to 36% of cases, but this tissue stems from the "free margins" from patients with breast 
cancer, and may therefore have represented pre-cancerous state that was not yet microscopically 
detectable. 22% of adenosis samples were also positive for TK1, indicating that TK1-expression may 
be an early event in the development of breast cancer (Alegre et al., 2012). In this study, a lymph node 
was analyzed from a lymphoma patient. This particular lymph node was rendered not to be involved 
by the lymphoma, but drained the particular area where the lymphoma was situated. This lymph node 
had high expression if thymidine kinase. This might indicate that activity can be detected earlier in the 
disease progression, and that TK might be an aid in the determination if prognosis if the method is 
refined. This could be in agreement with the findings by Alegre et al regarding the free margins of 
mammary tumors. Further assessment of thymidine kinase should involve the sampling of primary and 
secondary tumors as well as lymph nodes, to determine the distribution of the expression of thymidine 
kinase 1 more precisely.  
 
Expression of TK1 was very weak in mammary tumor samples in this study and could not be assessed 
as positive without high levels of subjectivity. Some degree of staining was apparent, but not to a 
greater extent than that found in normal epithelium. However, staining became apparent in 
lymphocytic infiltrates found in the capsule of one mammary tumor in particular (images below). 
There was also presence of positive cells in the stroma. The method has to be further assessed for 
mammary tumors in particular and is not considered for clinical use as of date. The dilution of the 
antibody was 1:200, and a lower degree of dilution might be considered. However, it might be of value 
to try a new detection system and a new antibody first and foremost, to determine if detection of TK1 
in mammary tumors could be of value. It appears that cells of lymphocytic origin express TK1 to a 
higher degree than cells of epithelial origin, even after neoplastic transformation. It is not uncommon 
to spot lymphocytes in the surrounding capsule enclosing a mammary tumor. These cells frequently 
expressed thymidine kinase. This may implicate that these tumors are an active part of the immune 
system against the tumor, but it may also suggest that they have a role in aiding the progression of the 
mammary tumor. 
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Fig 12 (upper left), 13 (upper right), 14 (lower left) and 15 (lower right). 20X. Example of the 
strongest staining intensity observed in mammary tumors in this study (a tubular carcinoma, simple 
type) This carcinoma has high degree of lymphocytic infiltration adjacent to the capsule. Note the 
expression of thymidine kinase in the lymphocytic infiltrates (fig 12 shows staining with hematoxylin – 
eosin, fig 13 shows immunohistochemical detection of TK1). In fig 14, we see the staining intensity in 
the parenchyma of the tumor, which is similar to that observed in normal epithelium (fig 15). The 
staining intensity of the tumorous parenchyma seen in this picture represents the strongest staining 
intensity obtained in the mammary tumor group in this study. The staining of the milk can be due to a 
reaction with the LSAB system and lactoperoxidase in the milk.  
 
Whether or not thymidine kinase is an aid the detection of metastasis could not be determined in this 
study, and future studies are necessary. More research is required for TK-analysis in tissue samples to 
become clinically available, especially regarding solid tumors. In human samples, thymidine kinase 
expression as determined by immunohistochemistry is significantly related to survival in patients 
suffering from adenocarcinoma of the lung (Xu et al., 2012). In the study by Xu et al, Envision and 
the monoclonal antibody from SSTK Ltd in Shenzhen, China, was used. Renal cells from humans 
have been studied using the XPA210 antibody. It has been established that expression of thymidine 
kinase in renal carcinomas accurately reflects the malignancy of the tumor, and that it is significantly 
different than the expression in normal renal tissue (Kruck et al., 2012). However, results on human 
solid tumors have been conflicting. Other studies have found levels of TK1 to be naturally higher in 
normal tubular epithelium than in tissues affected by renal carcinoma or normal glomerular cells (Luo 
et al., 2010). TK1 has been found to be expressed in squamous cell carcinomas of the uterus and 
esophagous, and adenocarcinomas of the gastrointestinal system. In this study, the F12 antibody by 
Abnova was used (Shintani et al., 2010). In a study using the antibody clone F12 from Abnova, 
Taiwan, TK1-expression was significantly increased in cases of gastric and esophageal carcinoma. In 
this study, lung adenocarcinomas and renal carcinomas were often negative regarding TK1-expression 
(Shintani et al., 2009). In this study, thymidine kinase was also expressed in the nucleus. 
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One problem is that immunohistochemical studies on TK1 have been performed with human tissue 
rather than canine tissue, making comparability to this study somewhat difficult. There are important 
similarities between dogs and women regarding the progression of cancer in the breast or udder. Those 
similarities include the array of receptors that are important in the carcinogenesis late in both dogs and 
humans. For example, there is a 25% overlap in the genetic profile of metastatic mammary carcinomas 
in canines and humans. The overlapping genes are mainly linked to proliferation, growth, 
transcriptional regulation, DNA repair, translation and kinase activity (Klopfleisch et al., 2010). The 
van´t Ver 70 genetic profile is used to find human breast cancer patients at risk of developing 
metastases. 34 out of 70 genes in this panel have been identified in the dog, but 68% out of those 34 
are of importance to the metastatic potential of canine carcinomas (Klopfleisch et al., 2010). None of 
the mammary tumors showed a significant expression of thymidine kinase 1, despite the fact that this 
has been proven to be true in human tissues. This could be due to a species-specific difference, or a 
factor in the pathogenesis of mammary tumors as discussed below. 
 
Aspects in the pathogenesis of mammary tumors influencing the outcome of 
the study 
The extent to which hormones affect the development of mammary tumors has long been the subject 
of scientific studies. 80-100% of all intra epithelial lesions express the estrogen receptor. The 
expression of the estrogen receptor is downregulated in high grade changes such as atypical ductal 
hyperplasia or carcinoma in-situ (Antuofermo et al., 2007). It has been shown that the estrogen 
receptor (ERa) and progesterone receptor (PR) is expressed to a greater extent in benign than 
malignant tumours (Chang et al., 2009). Reduced expression of these receptors has been associated 
with increased tumor size, lymph node metastasis and other metastasis (Chang et al., 2009). 
Expression of ER in humans with breast cancer is related to the mitotic index as measured by Ki67. In 
humans, PR is associated with lower frequency of metastasis, smaller tumor size and lower mitotic 
index. The lack of expression of ERa and PR is associated with poorer prognosis in both women and 
canines (Chang et al., 2009). The expression of ER and PR was not investigated in this study, and it 
was therefore not possible to establish whether the expression of these receptors constituted a 
confounding bias. However, 40% of the mammary tumors in this study were benign. As previously 
mentioned, the expression of ER and PR has been found to correlate with the mitotic index as 
measured by Ki67. It has not been shown how the expression of female sex hormones is correlated to 
the expression of thymidine kinase.  
 
One bias in this study is that we did not have access to any inflammatory carcinomas. It would be of 
interest to assess the expression of thymidine kinase in mammary tumors of higher degree of 
malignancy. Female sex hormones can induce synthesis of other factors which also contribute to 
cellular proliferation. Further studies are necessary to assess if this also applies to the expression of 
thymidine kinase. However, the susceptibility of mammary tumors to female sex hormones might be a 
confounding bias in the assessment of thymidine kinase expression. It would be advisable to also test 
the method on solid tumors of another origin.  
 
Future studies 
Micrometastases can be hard to detect, and this has been established in previous studies (Kohlberger et 
al., 2001). It is a possibility that thymidine kinase detection immunohistochemically is a more 
sensivite method for detection of cellular activity than ocular inspection. In this study, we could find 
cells that were clearly positive to thymidine kinase in tissue samples that were not neoplastically 
involved by ocular inspection. In the future, studies should also be focused on samples of peripheral 
lymph nodes from animals with neoplasia, and not just the primary tumors. Similarly, thymidine 
kinase might be a useful tool in differentiating cutaneous lymphoma from cutaneous inflammation. 
For this to be assessed, cutaneous biopsies from animals with non-neoplastic cutaneous disorders 
should be assessed as well. Also, it would be of interest to examine serum samples and biopsies from 
patients before and after chemotherapeutic treatment, and for this type of study, live animals have to 
be included. Perhaps thymidine kinase can be used to evaluate MRD if the method is refined. If so, 
this could be of use to determine treatment results, and an aid in selecting patients in need of 
chemotherapeutic treatment after surgery.  
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However, this requires control over the sampling process, to ensure that the peripheries of the tumors 
are included in the samples. We did not get clear signals from the mammary tumors in this study. 
However, they were 40% benign and many of them were of low degree of malignancy (35 % were 
diagnosed as complex carcinoma, 7/20 tumors). In future studies, tumors of higher degree of 
malignancy should be included, and inflammatory carcinomas be investigated.  
 
One problem with immunohistochemistry is the aspect of sample preparation and morphology. It 
would therefore be of interest to evaluate the expression of thymidine kinase in tissue samples by other 
methods, such as Western blot or dot blot. Another aspect is to attempt to detect the expression of 
mRNA rather than protein immunohistochemically to eliminate the bias of postmortal 
proteindenaturation. Another approach is to perform protein extraction on tissue samples to lower the 
degree of subjectivity in the analysis. First step is to tailor an antibody from a canine epitope, to ensure 
specificity to canine TK1. Also, it would be advisable to try other detection systems to lower the 
degree of background staining. In this study, an AUC-curve could not be calculated since there is no 
golden standard protocol for this type of analysis as of date. The method needs further assessment for 
this to be established.  
 
CONCLUSIONS 
The method needs further evaluation regarding morphological aspects in the treatment of tissue 
samples, the antibody and the use of LSAB as detection system. It appears that lymphocytic tissue is 
more prone to express TK1, and that T-cell lymphomas express TK1 to a greater extent than B-cell 
lymphomas. This could be of future use in the detection of minimal residual disease. The expression of 
TK1 by mammary tumors in this study was inconclusive and weak due to background staining in 
combination with weak signal intensity. One bias was the proportion of benign lesions and the lack of 
inflammatory carcinomas. In future studies, it would be interesting to sample the periphery of the 
tumors to determine whether or not this technique is of use in postsurgical histological assessment. 
Regional lymph nodes from patients with neoplasia should also be evaluated in conjunction with the 
primary tumors. It would also be of interest to examine TK1 activity in serum samples simultaneously, 
to determine the level of agreement in the expression of thymidine kinase 1 in serum samples versus 
tissue samples.  
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APPENDIX I – PATHOGENESIS AND HISTOLOGY OF CANINE MAMMARY 
TUMORS AND LYMPHOMAS 
The pathogenesis of mammary tumors and lymphoma  
Although uncontrolled proliferation is essential for the development of cancer, the pathogenesis is far 
more complex and cannot be reviewed in its entirety here. However, it is important to recognize some 
specific factors that might influence the different biological behavior patterns of these canine 
mammary tumors and lymphoma.  
 
The estrogen receptor, ER, is expressed in 65% of tumors of human breast cancer patients, and 50% of 
mammary tumors from dogs (Yang et al., 2006). ER and PR are not expressed at all inflammatory 
carcinomas (Millanta et al., 2010). 51.5% of patients expressing both ERa and PR respondend well to 
tamoxifen therapy, compared with 16.7% of the patients who only expressed ER in their tumors 
(Chang et al., 2009).ER, is expressed more in benign than malignant tumors and has a positive 
correlation with the expression of BCL-2 in dogs with mammary tumors. This may imply that ER 
controls the expression of BCL-2, as is the case with human breast cancer patients (Yang et al., 2006). 
BCL-2 is a protein that regulates apoptosis. It is also used to differ follicular lymphoma from 
hyperplasia in human patients. Expression of BCL-2 is related to better prognosis and reduced 
proliferative activity of the tumor.  
 
One aspect that distinguishes dogs from humans regarding the pathogenesis of mammary tumors, is 
that canine mammary tumor tissue expresses PR to a greater extent than ER (about 70% and 50% 
respectively). The opposite is true for humans: malignant tumors more often express ERα than PR 
(between about 70-80% compared to between approximately 50-70% expressing the PR). Why this 
correlation has been observed is unclear. One explanation is analytical error, since the expression of 
PR is dependent on the expression of ER (Chang et al., 2009). The expression of ER, PR and ErbB2 
(epidermal growth factor receptor 2) has an impact on survival rates (overall survival rate) in dogs and 
women with breast cancer (Klopfleisch et al., 2010). ErbB1 is also called EGFR and ErbB2 is also 
known as HER2/neu (Human Epidermal Growth Factor Receptor 2). 2/3 of all high grade carcinoma 
in-situ in dogs express HER2 (Antuofermo et al., 2007), and no difference in the HER2 expression 
was observed in inflammatory carcinomas compared to non-inflammatory carcinomas (Millanta et al., 
2010). With regards to the ectopic cartilage formation observed in benign mixed tumors, bone 
morphogenetic protein 6 (BMP-6) and its corresponding receptors BMPR-IA, BMPR-IB and BMPR-II 
are thought to participate in the regulation of cartilage formation. The ligand and its receptors are 
expressed in myoepithelium and chondrocytes within the tumors (Akiyoshi et al., 2004).  
 
Factors influenced by female sex hormones include GH and IGF1 in an autocrine fashion through 
progesterone P4. In humans, it has been shown that GH induces the growth of breast cancer tumors. 
There is a higher concentration of GH and IGF-I in malignant tumors compared to benign tumors and 
dysplasias in dogs (Queiroga et al., 2008). Autocrine production of GH in human tumors may lead to 
metastasis. It has been shown in human samples that expression of the sex hormones progesterone 
(P4) and estradiol-17B correlates with expression of GH and IGF-I. Progesterone seems to be able to 
induce expression of GH in breast cancer tumors in both dogs and humans. There is evidence that 
estradiol and IGF-I have a synergistic effect on tumor growth in both dogs and humans. One possible 
explanation is that estrogens sensitize cells to mitotic stimulus from IGF-I (Queiroga et al., 2008). 
 
There are studies suggesting that the insulin receptor may play a role in the carcinogenesis of breast 
cancer in humans. The expression of the insulin receptor might be downregulated in breast tissue in 
patients with carcinoma. Whether or not this correlation is significant has not yet been investigated in 
epidemiological studies. Studies on rats have shown that administration of insulin may cause induction 
of mammary tumors experimentally. The expression of the insulin receptor is strong in adenomas and 
normal mammary glands in dogs. The expression significantly reduces in mammary carcinoma and 
metastases, which can be visualized by detection of mRNa and protein immunohistochemically 
(Klopfleisch et al., 2010). 
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Mammary tumors are solid tumors and are dependent of different oncogenes than lymphomas for their 
growth. Adhesion molecules are of importance to the development of mammary cancer. One bias in 
this study, is that we did not have the opportunity to examine any grade III tumors. Benign mammary 
lesions tend to express E-cadherin more frequently, and the decreased membranous expression of this 
adhesion molecule is associated with increasing degree of malignancy, metastasis and local invasion 
(Genelhu et al., 2007). Eukaryotic Elongation Factor 1 delta (EEF1D) is also upregulated in dogs with 
mammary tumors. In humans, EEF1D is associated with oncogenic transformation and invasiveness of 
breast cancer tumors (Klopfleisch et al., 2010). In addition to increasing the rate of proliferation in 
cells, EEFD1 may also inhibit E-cadherin dependent cell-cell interaction, and thereby increase the 
invasiveness of the tumor. Expression of E-cadherin and β-catenin is related to tumor invasiveness, but 
has not been significantly correlated to survival (Brunetti et al., 2005). In humans, an elevated level of 
β-catenin is associated with poor survival in patients with adenocarcinoma of the breast (Méniel et al., 
2005). Moreover, expression of E-cadherin and B-catenin is not related to mitotic indices as measured 
by Ki67 (MIB1) or AgNOR (Brunetti et al., 2005). Historically, immunohistochemistry directed at E-
cadherin expression has been used to differentiate histiocytomas in the skin from other tumors of 
round cell origin. However, epitheliotropic lymphomas frequently express E-cadherin and this may not 
be as useful as previously assumed (Ramos-Vara and Miller, 2011).  
 
It has been proven that genetic components are important for the development of mammary tumors. 
Breast Cancer Suseptibility Gene 1 (BRCA1) is a famous suppressor gene detected in people with 
breast cancer. BRCA1 is expressed in its non-mutated form in normal mammary tissue in dogs (Kim 
et al., 2010). BRCA1 is a nuclear phosphoprotein. Reduced expression of BRCA1 in the nucleus, and 
increased expression of the protein in the cytosol is associated with increased malignancy, increased 
proliferation as measured by Ki67 and reduced expression of ERα (Nieto et al., 2003). The normal 
function of BRCA1 is to repair oxidative damage on DNA strands that would otherwise cause stress in 
the cell and inhibit replication (Kim et al., 2010). BRCA1 also has role in apoptotic control and cell 
cycle checkpoints (Im et al., 2013). Suppressor genes associated with breast cancer such as BRCA1 
and BRCA2 can be detected in 5-10% of human cases (Im et al., 2013). BRCA1 is rarely expressed 
the mutant form in benign mammary tumors, and much more in malignant metastatic mammary 
tumors (Kim et al., 2010). However, there are breed differences in the expression of the BRCA1 gene, 
the shih tzu breed often expressing more BRCA1 and also having mammary tumors with higher 
proportion of invading cells in the lymphatic system (Im et al., 2013). The prevalence of mutant 
BRCA1 genes is higher in families affected by hereditary breast cancer than for the rest of the 
population (Im et al., 2013). 
 
In some models explaining carcinogenesis, Tumor Initiating Cells (TIC) are suggested to play a 
significant role. Cell populations expressing the progenitor markers CD34, CD117 and CD133 have 
been detected in canine B-cell lymphomas. These cells coexpress the B-cellsmarkers CD21/CD22. 
These B-cells also exhibit genetic deviations in the IgH region (Immuno-Globulin Heavy Chain), a 
mutation detected in the tumor cell population in general. The cells also had the ability to proliferate in 
tissues of immunosuppressed mice, indicating that the progenitor cells with lower degree of 
differentiation may have great importance for the development of lymphoma and other neoplastic 
conditions (Ito et al., 2011). Regarding interleukin expression, human DLBCL-cells have been found 
to overexpress the IL-9 receptor. This interleukin is mainly secreted by T-helpercells, suggesting that 
this cytokine may act as a factor promoting tumor growth in addition to immune system signaling (Lv 
et al., 2013). 
 
T-helper cells in follicular lymphoma express IL-4 and CD40 ligand, leading to subsequent expression 
of CCL17 (a thymic and activation regulated chemokine) and CCL22 (chemokine derived from 
macrophages) from neoplastic cells (Rawal et al., 2013).  In cultures of follicular lymphoma cells ex 
vivo, CCL22 is spontaneously produced while CCL17 seems to depend on paracrine signals. CCL17 
and CCL22 are also overexpressed in Burkitts lymphoma, Hodgkins lymphoma, CCLs, mantle cell 
lymphomas and DLBCLs. There is a synergism in the expression of IL4 and CD40L when it comes to 
production of CCL17 and CCL22. The chemokines induce further expression of T-cells producing IL-
4 and not interferon producing cells, leading to immunosuppression in the microenvironment of the 
tumor and further promoting tumor growth (Rawal et al., 2013). This research has been done on 
human samples.  
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In humans, the herpesvirus known as Epstein-Barr is thought to potentially cause epithelial and 
hematological neoplasms. Recently, an oncogenic herpesvirus has also been found in the B-cells of 
dogs with lymphoma through electron microscopy (Huang et al., 2012).  
 
Attempts have been made to tailor a vaccine using CD40+ cells, in an attempt to trigger CD4+ and 
CD9+ T-cells in the immune system in patients with lymphoma. Trials have shown initial promise in 
canine patients with lymphoma immunized with triggered CD40-activated B-cells (Sorenmo et al., 
2011). Immunization with adenovirus vectors carrying CD40-ligand has also been attempted in canine 
patients with lymphoma. CD40 is expressed on B-cells and receptor binding induces differentiation of 
these cells. However, integration of the vector requires expression of αvβ3/5 integrins on the surface of 
lymphoma cells, a molecule which canine lymphoma cells do not seem to express (O´Neill et al., 
2011).  
 
One bodily defense mechanism is to force the cells into controlled cell death, apoptosis. Lymphoma 
cells may possess the ability to evade apoptosis through expression of survivin protein that prevents 
cells from apoptosis. Survivin is included in the IAP (Inhibitors of Apoptosis Proteins). Survivin can 
be detected immunohistochemically in up to 82% of lymphoma cells (Wimmershoff et al., 2010). 
However, it is not yet known to what extent normal tissues express survivin and more studies are 
necessary to establish the significance of different oncogenes in the development of lymphoma. 
 
A range of molecules have been investigated with regards to the expression found in dogs with 
intestinal lymphoma compared to dogs with inflammatory bowel disease (IBD), as these can be hard 
to distinguish histologically. One example is perinuclear antineutrophilic cytoplasmic antibodies 
(pANCA) in the neutrophils of humans affected by IBD. It has been proposed that lymphocytic-
plasmacytic enteritis (IBD) may progress to lymphoma eventually (Mancho et al., 2011). These 
antibodies are present in serum in dogs with both lymphoma and IBD. Perhaps this molecule is of 
value in the pathogenesis of both diseases. However, it is not of clinical use in the distinction between 
the diseases as of date (Mancho et al., 2011).  
 
The dog has served as a model animal in studies on lymphoma, and lymphoma specimens of canines 
and people do indeed share some similar traits when it comes to pathology. Contrary to previous 
studies in humans with DLBCL, it has been shown that the expression of BCL-6 is not related to 
prognosis and overall survival time in dogs with high grade lymphoma. (Sato et al., 2012). BCL-6 is a 
transcriptional repressor gene suppressing the anti-apoptitic effects of NFκB, i.e. nuclear factor kappa 
beta. NFκB is an important transcriptional factor in the pathogenesis of lymphoma, particularly 
DLBCL in humans. Activation of NFκB drives genes regulating proliferation (cyclin D1 and D2) and 
inhibition of apoptosis (for example BCL-2). Inhibition of NFκB in in vitro cultures of malignant 
canine B-lymphocytes leads to apoptosis and inhibited tumor growth (Gaurnier-Hausser et al., 2011).  
 
Leukemia is a hematopoetic malignancy present in the blood stream. FMS-like tyrosine kinase 3 
(FLT3) is often mutated in human patients with leukemia, which has recently been found to be the 
case for some dogs with acute lymphoblastic leukemia as well. It is expressed on lymphoid and 
myeloid progenitors and is involved in the regulation of normal differentiation and cell survival in the 
hematopoiesis (Suter et al., 2011). Signaling pathways involved in the FLT3 activation cascade 
include MAP (mitogen activated protein) and STAT (signal transducers and activation of 
transcription). Lymphoma specimens of dogs and humans overexpress high-mobility group box 
protein 1 (HMGB1), a protein promoting inflammation, neovascularization and DNA-binding. 
HMGB1 signaling is conveyed via toll-like receptors and RAGE (activated glycation end-products), 
leading to activation of NFκB, cytokine expression and VEGF (vascular endothelial growth factor) 
activation. However, even though HMGB1 is upregulated in lymphoma samples from dogs, RAGE 
levels did not differ from the control groups in the referenced study, indicating that HMGB1 may play 
a different role in exerting its extracellular effects (Sterenzcak et al., 2010). Another similarity 
between dogs and humans with hematopoetic neoplasms, is the fact that a low expression of major 
histocompatibility complex class II (MHCII) on lymphocytes of canine and human patients with B-
cell lymphoma negatively affects the prognosis (Rao et al., 2011). This may implicate that loss of 
MHCII reduces the immune response elicited by the tumor, allowing increased tumor progression to 
remain undetected by the immune system.  
 31 
 
 
One famous suppressor gene mentioned in the section “The concept of tumorigenesis”, is the p53 
gene. This gene is important to the development of both lymphoma and mammary neoplasia. In rats, 
20% of female rats heterozygous for p53 knockout develop breast cancer. Out of those, 70% express 
the estrogen receptor. Homozygous knockout rats develop lymphoma and sarcoma with early onset, 
and are more readily prone to metastasis (Yan et al., 2012). It has been shown that p53 and p21 are 
both up-regulated in areas of metaplasia in the mammary gland cells of mice with B-cathenin 
dysregulation, suggesting a protective effect of p53 against the actions of B-catenin. In mice with loss 
in the Apc-locus and p53, neoplastic development is clearly accelerated. Apc-loss on its own leads to 
metaplasia and not neoplastic development (Méniel et al., 2005). Loss of p53 leads to activation of the 
NFκB signaling pathway in a mouse model expressing TAX, a human leukemia virus oncoprotein 
(Ohsugi et al., 2013). However, cell cycle regulatory factors are also of importance to the development 
of lymphoma. In human studies, it has been proven that overexpression of cyclin D1 is of importance 
to the development of mantle cell lymphoma, whereas cyclin D2 is of greater importance to the 
development of DLBCL. Cyclin D2 is overexpressed in 98% of CD5+ DLBCLs, suggesting a role of 
cyclin expression not only in the overall development of lymphoma, but also in the differentiation into 
different subgroups of lymphoma (Igawa et al., 2013). 
 
T cells have been shown to have great significance in the development of breast cancer in women. B-
lymphocytes are dominant only in the early stages of carcinogenesis.  Lymphocytes migrate into 
mammary and breast tumors in both women and canines. In humans, it has been shown that presence 
of T-and B-cells is significant both in the defense against tumors, and to the progression of the tumor. 
These cells possess the ability to express cytokines (Tumor-Necrosis Factor alpha, Interleukin IL 4, 6, 
10 and others). The tumor itself can also produce cytokines as way to promote its own growth (Kim et 
al., 2010). Recently, regulatory T-cells were found to be increased in number in dogs with lymphoma, 
and CD4+ and CD8+ T-cells are less susceptible to mitotic stimulus than T-cells from healthy dogs 
(Mitchell et al., 2012). It has been shown in lymphoma specimens of DLBCL of the central nervous 
system in humans, tumor cells may stimulate their own growth through expression of B-cell activating 
factor (BAFF) receptor and ligand in an autocrine fashion. BAFF belongs to the tumor necrosis factor 
family. Furthermore, proliferation inducing ligand (APRIL) and its corresponding receptor was also 
expressed in CD20+ cells (B-cells), indicating that the BAFF/APRIL signaling pathway may play an 
important role in the pathogenesis of these tumors (Birnbaum et al., 2013). The expression of 
cytokines may assist the neovascularization process and paradoxically facilitate tumor growth. In 
dogs, it has been found that the lymphocyte population in the tumor mainly consists of T-cells rather 
than B cells (three times more T-cells than B-cells). Expression of IL1 and IL6 can be associated with 
metastasis and expression of both these cytokine can be seen in metastatic mammary tumors (Kim et 
al., 2010). IL-1 may directly affect the proliferation, act as a chemokine for nearby leukocytes and 
increase neovascularization. It has been shown that malignant mammary tumors often express the 
inflammatory enzyme COX-2 (more information on this may be read in the section “Treatment 
options for mammary tumors and lymphoma and follow-up of treatment outcomes”). However, this 
has been proven not to be the case in epitheliotropic T-cell lymphoma, suggesting that this enzyme 
may not play a significant role in the ulceration and inflammation observed in these tumors (Bardagi et 
al., 2012).  
 
It has been demonstrated in humans, dogs, cats and horses that there is a shift in the lymphocyte 
population with increasing age. It is mainly the T-cell dependent immunity that becomes affected: the 
number of CD4+ decreases and CD8+ T-cells increase. Meanwhile, the total number of peripheral 
lymphocytes decreases. T-cells have an important role in the defense against neoplasias. The ratio of 
CD4 +/CD8 + cells was significantly higher in people with cancer dogs than in dogs that had simply 
gotten older. The CD4/CD8-ratio declined with increasing age, but increased in dogs suffering from 
cancer compared to healthy dogs of the same age (Watabe et al., 2011). 45% of peripheral 
lymphocytes could neither be identified as B-or T-cells in dogs suffering from neoplasia, while all 
lymphocytes could be classified among the healthy dogs.  
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Histological classification of mammary tumors and lymphoma  
Mammary tumors are considered to incur after the progression of preneoplastic lesions to invasive 
carcinoma. This progression has also been described for people with breast cancer, and the 
preneoplastic lesions are known as IELs (Intra Epithelial Lesions). Progression to cancer proposedly 
starts with adenosis, which then becomes sclerosing and develops into an intraductal papilloma, and 
further into a sclerosing papilloma. This is followed by ductal hyperplasia and finally a ductal 
carcinoma in situ has arisen (Antuofermo et al., 2007). Carcinoma in situ is defined as the occurrence 
of malignant cells which have not yet penetrated the basal membrane. The progression eventually 
proceeds as a tumorous growth. Small tumors often consist of lobular hyperplasia, adenomas or 
complex adenomas. However, malignant lesions can arise from within benign tumors, which together 
with the increased incidence of multiple tumors in mammary cancer patients speak of a progressive 
development. Malignant tumors more frequently found in older individuals, and this applies to both 
canines and women (Sorenmo et al., 2009). 
 
Mammary tumors are classified on the basis of histological characteristics. Benign mammary tumors 
and lesions classified as cysts, gynecomastia, ductal hyperplasia, lobular hyperplasia or fibrosis 
usually carry a good prognosis. Benign tumors consist of adenomas (simplex, complex, basaloid), 
fibroadenoma, benign mixed tumors or ductal papilloma. Cytology and aspirates unfortunately have 
low importance for the determination of malignancy, due to the fact that the cells of the mammary 
gland can range from hyperplastic to apoptotic within the normal estrous cycle of the bitch. Moreover, 
malignant tumors may sometimes reside within a benign tumor, making the aspirate technique 
insufficient for diagnosis. However, a fine needle aspirate can help differentiate between mammary 
tissue and tumors of other cell lineages, such as mastocytoma and lymphoma, and other conditions 
such as inflammation (Dobson and Lascelles, 2011). The criteria on which malignancy is determined 
does not differ from any other tumor type: anisocytosis, anisokaryosis, basofilia, an increased number 
of nucleoli and cellatypia are all signs of malignancy. Mammary cancer tumors often tend to 
metastasize via the lymphatic route to mainly lung tissue (Clemente et al., 2010), and there are even 
reports on skeletal metastasis to the ribs (Dobson and Lascelles, 2011). Carcinomas are classified 
according to cell lineage and the degree of differentiation, according to the WHO system adapted by 
Misdorp et al 1999:  
 
• Adenocarcinoma complex: highly-differentiated tumors that still contain glandular 
structures and myoepithelium. This tumor type rarely metastasizes. 
• Simple adenocarcinomas: these tumors do not contain neoplastic myoepithelium, and can be 
divided into alveolar, tubular, tubuloalveolar, papillary or papillary-cystic depending on 
growth pattern. Can give rise to metastases.  
• Solid carcinomas: do not contain ductal structure. They carry a guarded prognosis and often 
metastasize.  
• Anaplastic carcinoma: very poorly differentiated tumors with high propensity to metastasize 
via lymphatics and/or and the blood stream. This tumor type is clinically referred to as 
inflammatory carcinoma. This stems from the invasion of the local lymphatic vessels which 
gives the tumor an inflamed appearance. These tumors have very poor prognosis and often 
metastasize in of both dogs as humans (Clemente et al., 2010). 
• Specific types of carcinomas include spindle cell carcinoma, squamous cell carcinoma, 
mucinos carcinoma or lipid rich carcinomas.  
 
In addition to the validated method of analysis of canine mammary neoplasms by Misdorp et al, the 
Elston and Ellis grading method has been described for grading of canine mammary tumors 
(Karayannopoulou et al., 2005).  
 
It has been shown that inflammatory carcinoma of the breast tissue in dogs and humans exhibit 
"vasculogenic mimicry" (VM), i.e., neoplastic cells that form capillary-like channels which are not 
covered by normal epithelium. This has been proposed as a way for the tumors create 
neovascularization and be locally invasive into surrounding lymph vessels (Clemente et al., 2010).  
 33 
 
The frequency of vasculogenic mimicry is much higher in inflammatory carcinomas compared to non-
inflammatory carcinomas in dogs (33% vs 5%, equivalent to 1 case of the total number surveyed 
according to Clemente et al., 2010).  
 
This is consistent with research in vivo and in vitro on inflammatory carcinoma in women, i.e., 
inflammatory carcinomas express vasculogenic mimicry to a greater extent than non-inflammatory 
carcinomas. This has been suggested to be a contributing factor to their proneness to metastasize and 
the clinical aggressiveness of the tumors. Co-expression of cytokeratin (CK), vimentin and 
vasculogenic mimicry has been observed in both dogs and women. In women, this co-expression is 
associated with a worse prognosis (Clemente et al., 2010). It has not yet been proven that vasculogenic 
mimicry is associated significantly with invasion of lymphatic vessels and lymph nodes in dogs, but 
can be used as a marker of the anaplastic dedifferentiation of neoplastic cells (Rasotto et al., 2012). 
VEGF is an important factor for the formation of lymphatic vessels, which are an essential part in the 
pathogenesis of inflammatory carcinomas since this condition is characterized by the local invasion of 
lymphatic vessels (Millanta et al., 2010). VEGF expression is much higher in inflammatory 
carcinomas compared to non-inflammatory carcinomas in dogs. This is consistent with studies in 
humans, and suggests that VEGF plays a significant role in the angiogenesis and the increased 
vascular permeability in inflammatory carcinoma in dogs and women (Millanta et al., 2010). 
 
Fig 16. Schematic and simplified illustration of the progression from normal epithelium to carcinoma 
in situ and finally, vascular invasion and vasculogenic mimicry 
 
 
 
Sarcomas make up 5-10% of cases. Sarcomas consist mainly of extraskeletal osteosarcomas or 
fibrosarcomas. Gomoris reticulin stain can be used to differentiate fibrosarcomas from spindle cell 
carcinomas (Karayannopoulou et al., 2005). The mammary gland is the most common localization of 
extraskeletal osteosarcoma, accounting for 64% of the tumors in this category (Langenbach et al., 
1998). The diagnosis of sarcoma is a risk factor for decreased survival postsurgically (Hellmén et al., 
1993). Sarcomas carry a poor prognosis and metastasize in 75% of cases (mainly via the 
hematogenous route). In rare cases, carcinosarcoma occurs in the mammary gland. Carcinosarcoma is 
a tumor of the mixed cellular lineage with both epithelial and mesenchymal origin. There are 
immunohistochemical tools available to distinguish different components within a tumor. Previous 
studies have shown that myoepithelial components exhibit five different patterns of growth within a 
tumor: spindle shaped interstitial cells, star shaped cells, cartilage, resting suprabasal cells and 
proliferative suprabasal cells. The transformation necessary for cartilage formation can be 
characterized by expression of a-actin, keratin components (no 19), S-100 protein and vimentin. 
Epithelial components are positive to keratin staining, connective tissue to staining for vimentin, and 
myofibroblasts to a-actin and vimentin respectively. Since myoepithelium makes up a significant part 
of a large number of carcinomas, this author suggests a new subdivision of pleomorphic carcinoma, 
including carcinomas except mucinous, squamous cell and comdeo carcinoma (Destexhe et al., 1993).  
Normal epithelium Carcinoma cells in situ 
Vascular invasion (left) and 
vasculogenic mimicry (right) 
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A homologue to p53, namely p63, can be used with high specificity for detection of myoepithelial 
components, since this molecule is not expressed in stromal components of the tumor (Gama et al., 
2003).  
 
Whether or not the myoepithelium has a significant role in the carcinogenes is still disputed. Highly 
differentiated myoepithelial cells have been shown to have a carcinostatic effect in vitro. 
Myoepitelioma in dogs is comparable compared to "basal-like" breast cancer in humans and have a 
worse prognosis than carcinoma complex. Differentiated myoepithelium express vimentin, and 
neoplastic myoepithelium expresses CD14 and p63. Myoepithelioma was not originally included in 
the WHO-classification system (Rasotto et al., 2012). However, there is an additional classification 
system according to Clemente et al. This corresponds largely with Misdorp et al. Both systems 
evaluate the degree of tubuli formation, nuclear pleomorfism and degree of mitosis.  
 
There are several classification systems for canine lymphomas, the most commonly accepted being the 
WHO-system, REAL-system and Kiel-system. The oldest systems include the Gall and Mallory 
system, introduced in 1942, and the Rappaport system, introduced in 1966. The Kiel-classification 
system was first established in 1974. It was based upon the suggestions that malignant lymphoma cells 
were in fact neoplastic versions of normal lymphocytes, and that substages of these cells would be 
represented as a progenitor lymphoid cell halted in their development (Parodi, 2001). Simultaneously 
in the seventies, other classification systems were proposed such as the Lukes and Collins 
classification system, the system by Dorfman and the WHO-classification system. For this reason, the 
Working Formulation was established in order to harmonize the different systems. Subsequently, the 
updated Kiel-classification system followed in 1990, the REAL-classification system in 1994, and the 
WHO-classification which was last updated in 2008 by Swerdlow (Parodi, 2001 and Swerdlow et al., 
2008). The Kiel-system has been utilized used by many authors for canine lymphoma. Scientific 
studies are ongoing to evaluate the comparability to the classification systems used in human medicine 
(Ponce et al., 2010). The WHO established the classification criterion for human lymphoma, which 
has been claimed as the consensus regarding classification of human lymphoma since 2008 (Campo et 
al., 2011). The ability to grade canine lymphoma according to subtype could constitute an opportunity 
to closely tailor the treatment of a specific patient. As in humans, different subtypes of lymphoma 
clearly exhibit different prognosis regarding therapy with cytostatic agents (Dobson, 2004 and Ponce 
et al., 2004). In the referenced study, small clear-cell T-lymphoma (updated Kiel classification system) 
had the longest overall survival time (almost 27 months), and since the T-cell lymphoma group is 
heterogenous, purely immunotyping the neoplasm may be insufficient to indicate prognosis. 
Immunohistochemistry of CD79 (expressed in B-cells) and CD3 (expressed in T-cells) has been of 
great value in distinguishing the two groups. Mycosis fungoides (epiteliotropic lymphoma), is defined 
as a disease cause by the proliferation of cells of T-cell origin (Moore et al., 1994).  
 
In humans, the term “Hodgkins lymphoma” is often used. This form of lymphoma is less common 
than the more often referenced non-Hodgkins lymphoma (NHL), and there is only 1 case of Hodgkins 
lymphoma for every case of non-Hodgkins lymphoma in humans. This disease exhibits a biphasic 
peak in incidence, the first peak in the first third of life and the second occurring after 50 years of age. 
Apart from an inflammatory infiltrate of mainly lymphocytes, plasmacells and histiocytes, the disease 
is histologically characterized by the presence of malignant Reed-Sternberg cells. The former Rye 
classification proposing 4 types of Hodgkins lymphoma has now been replaced by the WHO 
classification system (Tsang et al., 2006). In the pathogenesis of Hodgkins lymphoma, the expression 
of NFκB and infection of the Epstein-Barr virus have been associated with acquisition of the disease 
and disease progression.  
 35 
 
Recently, it has been found that loss of the kelch-domain protein KLHDC8B may be linked to the 
chromosomal instability observed in Reed-Sternberg cells (Krem and Horwitz, 2013).  
 
The dog has previously been used as a model animal for humans in lymphoma studies. Multicentric 
high-grade lymphoma in dogs is comparable with non-Hodgkins lymphoma in humans. 
Morphologically, one can find similarities between human lymphomas according to the WHO-
classification system for humans and the updated Kiel-classification system for dogs. The 
centroblastic and immunoblastic subtypes of high grade large B-cell lymphoma are overrepresented 
among adult dogs and can be compared with DLBCL (Diffuse Large B-Cell Lymphoma) in adult 
humans. DLBCL-group is also the most common type of lymphoma in adults and accounts for 30-
40% of all lymphomas in humans (Sato et al., 2012). One difference, however, is that the dog's 
centroblastic and immunoblastic lymphoma histologically includes the presence of MMC 
(Macronucleolated Medium-sized Cells), which is missing in the corresponding form of lymphoma in 
humans. The significance of this for the use of the dog as a model animal for humans is unclear.  
 
Burkitt-like B-cell-lymphoma has been observed in dogs and can be compared with Burkitt-type B-
cell lymphoma in humans. This type of lymphoma is defined by a "starry sky" pattern, medium-sized 
cells, round nuclei with condensated cromatin and high mitotic index. 80% of the dogs were positive 
for the mitosis marker Ki-67, compared with almost 100% of human samples. It is suggested that 
plasmacytoid B-cell lymphoma in dogs can be a variant of Burkitt-type in humans, with the exception 
that this tumor in dog lacks central nucleoli and starry-sky designs, has less cells and more finely 
dispersed chromatin. The study also shows that small lymphocytic B-cell lymphoma in dogs may be 
more difficult to compare with human samples that are classified according to the WHO system. Low-
grade B-cell lymphoma in dogs is classified as prolymphocytic, small lymphocytic and 
lymphoplasmacytic according to the Kiel classification system, while human classifications include 
chronic lymphocytic leukemia, mantle cell lymphoma, marginalzone lymphoma of the spleen, lymph 
nodes, MALT, lymfoplasmacytic and follicular lymphoma (Ponce et al., 2010). 
 
Histologically, a range of proliferation factors have been utilized to assess mitosis. Ki67 index is a 
way to determine the mitotic activity in tumors and Ki67 (MIB-1) is expressed in the nucleus. Ki67 is 
significantly related to the prognosis of human lymphoma patients with high-grade as well as low-
grade lymphoma (Flood-Knapik et al., 2012), and overall and disease free survival in human patients 
with breast cancer (Abboud et al., 2008). However, this has not been shown to have significance for 
prognosis in dogs with high-grade lymphoma. Regarding low-grade lymphomas in dogs, the mitotic 
index is highest among follicular lymphomas, and lowest in T-zone lymphomas and marginalzone 
lymphomas. Expression of Ki67 is not correlated to the median survival time for dogs with low-grade 
lymphoma (Flood-Knapik et al., 2012). In human patients with node-negative breast cancer, a mitotic 
index produced by combining percentage Ki67 (MIB1) positive cells and cells positive for another 
mitotic marker (AgNOR, argyrophilic nucleolar organizer region) is related to disease free survival 
and overall survival. AgNOR gives additional information regarding the length of the cell cycle, since 
the amount of AgNORs in interphase is directly related to the turnover of cells and speed of the 
individual cell cycle. Interphase AgNORs participate in the synthesis of ribosomal RNA and the size 
and number of AgNORs vary with the transcriptional activity within the cell (Abboud et al., 2008). 
The AgNOR area and reduced number of AgNORs per nucleus has been associated with longer 
disease free survival in dogs with lymphoma aswell (Kiupel et al., 1999). 
 
Another example of a mitotic marker used in clinical pathology is PCNA (proliferating cell nuclear 
antigen). PCNA is expressed to a greater extent in metastatic mammary tumors than in non-metastatic 
mammary tumors (Klopfleisch et al., 2010). PCNA increases replication by acting as a cofactor to 
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DNA polymerase delta. PCNA can also inhibit apoptosis by inhibiting tyrosine kinase-c-abl stability, 
as well as affect the RAD6-dependent DNA repair. RAN/TC4-binding protein (RANBP1) is 
upregulated in metastatic mammary tumors and in most human cancer conditions including breast 
cancer. It also has an influence on the proliferation of cells and prevents apoptosis. (Klopfleisch et al., 
2010). However, mitotic markers are not interchangeable in all circumstances. It has been previously 
described that the mitotic index as measured by Ki67 is indicative of the first relapse free interval in 
canine patients with lymphoma, but not the median overall survival time. The expression of PCNA 
was not indicative of neither. On multivariate analysis, it was shown that only a combination of the 
Ki67-index and apoptotic index (proliferation/apoptotic ratio, PAR) was indicative of the duration of 
first relapse free interval (Phillips et al., 2000).  
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APPENDIX II - CLINICAL ASPECTS 
Clinical staging of the canine cancer patient 
Staging of the patient is performed according to the TNM system established by the WHO. T stands 
for tumor and is assessed based on tumor size. Palpation of regional lymph nodes is performed to 
reveal possible enlargement. Enlargement of a regional lymph node may indicate metastasis and 
worsens the prognosis. Since the 5th mammary gland may be connected to the popliteal lymph node, 
palpation of this lymph node should not be neglected. N stands for node and M stands for metastasis in 
the TNM system, and staging is performed regarding possible metastasis to the lymph node or distant 
anatomical locations. Malignant mammary tumors generally are larger than benign tumors, on 
average, 4.7 cm compared to 2.1 cm in a study of 90 cases (Sorenmo et al., 2009). It has been shown 
that tumors measuring 5 cm or more are more likely to metastasize to local lymph nodes than smaller 
tumors (Chang et al., 2005). Over 60% of the dogs have more than one tumor, and dogs with 
malignant mammary tumors are more likely to develop more primary tumors than dogs with benign 
tumors. In women with breast cancer are also at risk of developing new tumors in the chest on the 
opposite side if they have already been diagnosed with breast cancer (Sorenmo et al., 2009). Palpation 
of the tumor reveals whether it is freely sliding against the underlying tissue, or if adherences have 
been formed. It has been shown that solid tumors (mammary tumors included) expressing adherence 
markers (for example galectin-1) may metastasize to lung tissue more efficiently (Ito and Ralph, 
2012). 
 
Table 7. Clinical TNM staging of mammary tumors, adapted from Cassali et al, 2011. 
T T0 No evidence of primary tumor  
T1 Tumor size < 3 cm a. Not attached 
b. Attached to the skin 
c. Attached to muscle 
T2 Tumor size 3-5 cm a. Not attached 
b. Attached to the skin 
c. Attached to muscle 
T3 Tumor size > 5 cm a. Not attached 
b. Attached to the skin 
c. Attached to muscle 
 T4 Inflammatory carcinoma (tumor of any size)  
N N0  No regional lymph node metastasis  
N1  Ipsilateral lymph node involved a. Not attached 
b. Attached 
N2  Bilateral lymph node involved a. Not attached 
b. Attached 
M M0  No distant metastasis  
M1 Distant metastasis present  
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Table 8. Grouping of TNM stages into clinical stages, adapted from Cassali et al, 2011. 
 T N M 
    
Stage I T1 N0 M0 
    
Stage II T0 N1a  
 T1 N1a  
 T2 N0 or N1a M0 
 
Stage III 
 
T3 
 
All N 
 
 All T All Nb M0 
    
Stage IV All T All N M1 
 
Inflammatory carcinomas of the breast in dogs and humans have similar clinical characteristics. They 
are locally invasive and cause local inflammation with erythema, warmth and tenderness, and can thus 
be mistaken for dermatitis in both humans and animals. The tumors are generally very aggressive and 
treatment is usually only palliative (Clemente et al., 2010). Survival at time of diagnosis of anaplastic 
carcinoma is only weeks long despite attempts of treating the condition. Therefore, it is the most 
aggressive mammary tumor in dogs and women (Clemente et al., 2010). Inflammatory carcinomas 
often metastasize to other tissues than non-inflammatory carcinoma. Inflammatory carcinoma never 
metastasize to bone tissue, and more rarely to the lung, liver and kidney. However, inflammatory 
carcinoma metastasizes to the bladder and urogenital area (Clemente et al., 2010). 
 
Staging of the canine lymphoma patient differs slightly from the one practiced in patients with solid 
tumors. Lymphomas can be categorized according to anatomical location, where the multicentric form 
accounts for approximately 80% of cases. In addition to the multicentric form, there is also an 
alimentary form, cutaneous form, mediastinal form and extranodal form. As much as 82,4% of the 
dogs with lymphoma have lymphadenopathy, and 17.6% suffer from extranodal influence (Ponce et 
al., 2010.) Clinical staging is performed according to the WHO system and takes into account the 
anatomic position of the lymphoma, as well as the patient's wellbeing. 
 
Table 9. Clinical stages of canine lymphoma, adapted from Jagielski et al, 2002 
 
Stage I Single lymph node or lymphoid tissue in single organ involved (not including bone 
marrow) 
 
Stage II 
 
Involvement of several lymph nodes, with or without involvement of tonsills 
  
Stage III Generalized lymph node involvement 
  
Stage IV Liver and/or spleen involved, with or without lymph node involvement 
  
Stage V Involvement of bone marrow, blood or extranodal locations 
                                      Substage a. without clinical signs of disease  
                                     Substage b. with clinical signs of disease 
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Clinical aspects relevant to the assessment of the canine cancer patient 
Investigation of a presumptive canine lymphoma or mammary tumor patient begins with the medical 
interview and physical examination. Once the diagnosis of mammary tumor or lymphoma has been 
established, further investigation is necessary to determine the prognosis of the patient. In patients 
with mammary tumors, increased production of GH (growth hormone) may occur. Treatment of 
female dogs with medroxyprogesterone acetate or proglistenone can cause local production of GH, 
IGF-I, IGF-II and IGF-binding proteins by the mammary gland, and the formation of benign 
mammary tumors (Mol et al., 1996). However, it has been shown that the production of GH can 
increase in malign tumors negative for the progesterone receptor in both canines and women (Mol et 
al., 1996). It has been shown that treatment with progestins of canines with pituitary dwarfism can 
significantly improve symptoms and increase production of IGF-I (Kooistra et al., 1998). Expression 
of IGF-I in patients with mammary tumors is associated with increasing tumour size, fast-growing 
tumors, ulceration and the formation of adherences to underlying tissues in dogs (Queiroga et al., 
2008).  GH-production might cause acromegaly in the patient (Mol et al., 1996 and Queiroga et al., 
2008). In this case, it is not possible to analyze GH, but IGF-1-assays for measurement in serum are 
available including the enzyme-labelled chemiluminescent immunometric assay (Immulite 1000 IGF-
1 assay, Diagnostic Products, Los Angeles, California, USA) which has been tested for use on canine 
serum (Tvarijonaviciute et al., 2011). Measurement of IGF-1 is not readily available in Sweden 
today.  
 
Hypercalcemia might occur as a paraneoplastic syndrome in lymphoma patients due to production of 
parathyroid hormone related peptide PTHrp. However, studies have failed to correlate the level of 
PTHrp with hypercalcemia in dogs with lymphoma, suggesting that another mechanism might also 
play a role in the pathogenesis. The connection between PTHrp levels and hypercalcemia could only 
be made for dogs with anal sac adenoarcinoma (Rosol et al., 1992). Canine lymphoma patients with 
hypercalcemia at the time of diagnosis have a shorter median survival time than those who do not 
(Elliott et al., 2013). A high level of calcium in the blood can cause polyuria/polydipsia, as described 
in case reports (Barthez et al., 1995 and Bae et al., 2007) and polyuria/polydipsia will be the result in 
80% of patients with hypercalcemia (Teske, 1994). Neoplasia is the most common reason of 
hypercalcemia in dogs, lymphoma being the most common neoplasia causing hypercalcemia 
(Bergman, 2012). 88% and 38% of dogs with hypercalcemia will get anorexia or vomit, 87% and 68% 
will get elevated urea or creatinin levels as a result of reduced glomerular filtration. Hypercalcemia is 
more commonly found in patients suffering from T-cell lymphoma (Teske, 1994). To make matters 
worse, complex carcinoma in the mammary gland may also induce production of PTHrp (Bae et al., 
2007).  In a study of Flood-Knapik et al, 25.3% of 75 dogs with low-grade lymphoma presented with 
lymphocytosis at the time of diagnosis (Flood-Knapik et al., 2012). Measurement of ionized calcium 
gives the most accurate clinical assessment, since ionized calcium reflects the levels of PTH and 
vitamin D. Neoplasia, particularly lymphoma, is the most common cause of ionized hypercalcemia in 
dogs (Messinger et al., 2009). Lymphocytosis, lymphopenia, anemia and thrombocytopenia may also 
be seen in blood samples (Teske, 1994). Myastenia gravis may be causally to cutaneous lymphoma, as 
described in a case report (Ribyard et al., 2000). Hyperlactemia is associated with hematopoetic 
malignancies in humans. However, the neoplasm itself is not thought to be the sole cause of 
hyperlactemia in dogs with lymphoma. 70% of hyperlactemic dogs with lymphoma have an additional 
cause of hyperlactemia and factors such as corticosteroid administration have been found to be 
significantly associated with the presence of this condition in canine lymphoma patients (Touret et al., 
2012). Mild proteinuria is often observed in patients with lymphoma. However, the presence of mild 
proteinuria is not thought to be clinically significant (Di Bella et al., 2013).  
 
In addition to blood samples, histology can aid the clinician in further examination of the patient. If 
lymphadenopathy is present, further examination can include a fine needle aspirate (FNA) or a biopsy 
of the affected lymph node. This applies to both patients with mammary tumors as well as lymphoma 
patients. When a FNA is performed, cells are extracted via a syringe and the method is less invasive 
than a biopsy. The procedure can often be performed without sedation. One disadvantage of FNA is 
that it can be harder to diagnose certain subtypes of low grade lymphomas, in which case the 
architecture of the lymph node might be crucial to set a correct diagnosis. (Ponce et al., 2010).  
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According to Sapierzynski et al, non-Hodgkin's lymphoma can be diagnosed based on aspirates in 80-
90% of human patients, however the subtype of the lymphoma can only be determined in 67-86% of 
all aspirates. (Sapierzynski et al., 2010). Change of diagnosis may occur in as much as 20.4% of after 
immunofenotyping with immunohistochemistry (Flood-Knapik et al., 2012). There is also the 
possibility of performing a bone marrow aspirate. There are research groups who consider this to be a 
necessity to make accurate diagnosis and prognosis of the patient (Marconato et al., 2008), and they 
are the research groups who believe that the procedure does not add anything regarding staging or 
treatment (Flory et al., 2007).  
 
Immunohistochemistry is a useful tool in the assessment of the canine cancer patient. Mantle cell 
lymphomas are aggressive tumors, and it is necessary to determine the mitotic index as a complement 
to the PAD to determine the prognosis since a small cell low-grade B-cell lymphoma can be 
transformed into high grade large B-cell lymphoma in some cases (Ponce et al., 2010). The 
International Lymphoma Study group has shown that the diagnostic accuracy increases by 10-45% for 
the diagnosis of mantle cell lymphoma, T-zone lymphoma and DLBCL using immunohistochemistry. 
Immunohistochemistry can help differentiate T-zone lymphoma from marginal cell lymphoma by 
immunhistochemical detection of CD3 and CD79a (Flood-Knapik et al., 2012). 
 
Thoracic x-ray imaging might reveal possible metastasis. As mentioned earlier, mammary carcinoma 
often metastasize to lung tissue. The occurrence of subpleural osteoma should not be confused with 
metastasis in older dogs. Ultrasound of the abdomen allows visualization of the internal organs, in 
search of metastasis or primary foci of lymphoma. A problem that persists with respect to diagnostic 
imaging is the user dependent factor that cannot be eliminated. There is also the issue with artefacts, 
for example the accumulation of intestinal gas which obstructs the sound waves when performing an 
ultrasound (Wisner et al., 2004). Flory et al argue for the ultrasound as a tool of diagnostic value for 
determining suspicious neoplastic changes in abdominal organs. (Flory et al., 2007). To determine the 
nature of the lesion detected on an ultrasound, biopsy or FNA sampling is required. This can 
sometimes be performed with ultrasonic guidance and sedation (Wisner et al., 2004). Despite this, it 
can be difficult to get an accurate diagnosis of the subtype of the lymphoma without genotyping as a 
complement (Ponce et al., 2010).  
 
Treatment options for mammary tumors and lymphoma and follow-up of 
treatment outcomes 
Mammary tumors in dogs are treated surgically. However, the success of treatment is determined by a 
number of factors. Metastasis to adjacent lymph nodes is more likely to occur if the tumor is 
discovered more than 6 months before initiation of surgery (Chang et al., 2005). In addition, the 
histological profile of the tumor plays a significant role. Spay status plays a more significant role 
regarding 2 year survival time postoperatively to dogs suffering from complex carcinoma than dogs 
suffering from simple carcinoma (Chang et al., 2005). In other studies, obesity, age at diagnosis and 
spay-status has not been shown to affect the outcome postsurgically. Obesity has been related to the 
development of mammary tumors in other studies (Pérez Alenza et al., 1998). Other studies have 
determined increasing age as a risk factor for decreased postsurgical survival (Hellmén et al., 1993). 
However, histological diagnosis of anaplastic carcinoma, evidence of metastasis and tumor size are all 
factors affecting treatment outcome. Dogs dying of tumor-related causes postoperatively have shorter 
survival time than those who die of other causes, 14 months vs 23 months (Philibert et al., 2003).  
 
72% of vets in England always recommend castration of female dogs that are not going to be used for 
breeding (Beauvais et al., 2012). When castration is performed has long been considered important for 
the dog's survival after treatment of a mammary tumor. Dogs castrated within a 2 year period starting 
from the date of surgery of their mammary tumors had a median survival time of 755 days compared 
with 301 and 286 for dogs castrated more than 2 years before the procedure, and intact dogs (Sorenmo 
et al., 2000). This author suggests that castration associated with mastectomy can be an adjuvant 
therapy in order to increase the patient's survival. Another study has found that the risk of developing 
mammary tumors is significantly reduced in bitches castrated before 2.5 years of age (Sonnenschein et 
al., 1991). Dogs treated with synthetic progestins in an experimental study had increased risk of  
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developing mammary tumors, but had no increased risk of developing cancer of the mammary gland 
(Misdorp, 1988). Treatment with medroxyprogesterone acetate (MPA) from 3 month to 1-15, years of 
age can induce the development of mammary tumors. However, these tumors were exclusively benign 
(Concannon et al., 1981). Other studies have failed to establish a statistically significant connection 
between castration early in life and protection against mammary tumors (Spain et al., 2004). Some 
authors claim that castration before first, second or third estrus reduces the risk of mammary tumors to 
0,5%, 8% and 26% (Antuofermo et al., 2007). Castration has been proposed as adjuvant treatment, 
because treatment with estrogen receptor blockers like tamoxifen in dogs increases the risk of 
pyometra, edema of the vulva and urinary tract infection (Chang et al., 2009). The British Small 
Animal Veterinary Association has recently released a review discussing supposed bias in these 
studies (Beauvais et al., 2012). Aspects such as the selection of study population, study design, 
confounders are considered. The role of sex hormones in the pathogenesis of mammary has been 
established in many scientific studies. 
 
There are drugs available to treat cancer of the breast in humas. The amino acid sequence in canine 
ErbB1 is 91% homologous compared with human ErbB1, ErbB2 exhibit 92% homology (Singer et al., 
2012). ErbB1 and ErbB2 is overexpressed in 3 or 4 out of 10 surveyed mammary tumors according to 
Singer et al, 2012. The binding site of cetuximab (anti-ErbB1) and trastuzumab (anti-ErB2) differed 
from the human epitope in 4 or 1 amino acids respectively. These antibodies can also inhibit the 
growth of canine mammary tumor (Singer et al., 2012).Those drugs are expensive and not widely used 
in dogs today. Treatment of mammary tumors with cytostatic agents such as 5-fluorouracil, 
doxorubicin and cyclophosphamide has been discussed (Sorenmo, 2003). However, mammary tumors 
in dogs may also express the enzyme cyklooxygenas2 (COX2). Unlike the isoenzyme COX1, COX2 is 
induced in the body. It catalyzes the conversion of arachidonic acid to prostaglandins, a family of 
inflammatory mediators (Queiroga et al., 2005). COX2 is induced in breast cancer tumors, and the 
highest expression of the enzyme can be found in inflammatory carcinoma. This has also been 
demonstrated in human breast cancer patients. COX2 is induced in malignant neoplasms and 
expression increases with the degree of skin ulceration and tumor size (Queiroga et al., 2005). 
Expression of COX2 is related to prognosis and this implicates that treatment with non-steroidal non-
inflammatory drugs (NSAIDs) may be indicated (Queiroga et al., 2005). 
 
Treatment of lymphoma is not curative, but rather focuses on extending and improving the quality of 
life of the patient. There are a number of different chemotherapy protocols, all of which must be 
carefully considered before they are applied to current patient to get the best results and minimize 
toxicity (Simon et al., 2006). Protocols are named with abbreviations based on the first letter of the 
constituent medications. A protocol used extensively is treat T-cell lymphoma is the CHOP Protocol, 
where CHOP stands for cyclophosphamide, hydroxydaunorubicin (doxorubicin), oncovin (vincristin) 
and prednisone. L-asparginase can also be added, an enzyme that is injected subcutaneously and is not 
a cytostatic agent. B-cell lymphomas are generally more chemosensitive than T-cell lymphomas, and 
the treatment outcome for such protocols varies between 60-90% for CR (Complete Remission) with a 
median survival of 6-12 months (Marconato et al., 2011). The addition of cytosine arabinoside 
enhances chances for remission and survival regardless of tumor phenotype in dogs with lymphoma 
affected by bone marrow infiltration (Marconato et al., 2008). Overall, remission rates vary from 75-
90% with overall survival times of 6-15 months. However, protocols containing doxorubicin generally 
produce a better response. One problem is identifying patients available for treatment. Although 60% 
of lymphomas are of B-cell origin, there is substantial variation in treatment response within the B-cell 
lymphoma group and immunophenotype alone is not sufficient to select which patient should be 
available for treatment (Dobson, 2004).  
 
Similarly to bacteria and parasites, tumors can become resistant to the medicines we use to treat 
cancer. This is called MDR (Multi Drug Resistance) and signifies that different patients with the same 
tumor type, the same history and the same clinical conditions respond differently to the same treatment 
protocols. This is due to the ability of tumor cells to continually transform genetically and 
epigenetically (Savage et al., 2009). The risk of MDR can be reduced by adding for example 
fludarabidine to the protocol, a drug that is not a substrate for P170-glycoprotein. Tumors that have 
grown refractory to CHOP protocol, or in case of relapse, a new treatment strategy might become 
necessary. One example is MOP Protocol, where mechlorethamin and procarbizine are added 
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(Northrup et al., 2009). Another example is the DMAC Protocol, containing dexamethasone, 
actinomycin D, cytosine arabinosid and melphalan (Alvarez et al., 2006). The goal is mainly to supply 
drugs that are not substrates for P 170. L-asparginas and lomustine (CCNU) are drugs used in 
combination with prednisolone to achieve improved therapeutic efficacy and survival (Saba et al., 
2007). Remission is obtained in 20-50% of cases in 2-3 months, and regardless of the protocol used to 
treat the patient, the risk of relapse and resistance to drugs remains a major problem (Saba et al., 
2007). In a cohort study with 127 dogs with lymphoma, 13% of patients lived > 2 years after their 
diagnosis. The patients who participated in the study had all been treated with chemotherapy in animal 
hospitals, where 12 of the 13 long-term survivors were treated according to the widely used CHOP-
protocol. One dog was treated with doxorubicin alone (Marconato et al., 2011). All 13 dogs had B-cell 
lymphoma. Sensitivity and specificity for this was 85% and 77% to identify dogs that survive > 2 
years after his diagnosis, however, was the negative predictive value is high (98%). Parameters 
assessed were the prevalence of hypercalcemia, bone marrow infiltration, weight, stage and hematocrit 
before initiation of treatment.  
 
In addition to chemotherapy treatment, radiation has also been suggested as an alternative (Vaughan et 
al., 2007). Bone marrow transplant has also been discussed (Frimberger et al., 2006). In these patients, 
it is important to establish the MRD (Minimal Residual Disease), but the methods and consensus on 
protocols for how this should be done have not been established. Protocols are being evaluated and a 
polymerase chain reaction (PCR) method for this is being developed. In a Japanese study, 29 dogs 
with high-grade B-cell lymphoma according to the Kiel classification system and lymphadenopathy 
were treated with chemotherapeutic agents according to the University of Wisconsin-Madison 
chemotherapy protocol (UW25, vincristine, doxorubicine and cyclophosphamide). 27 of the dogs were 
in CR, 2 of the dogs reached partial remission. Neoplastic lymphocytic cells in peripheral blood was 
determined by PCR-analysis. The PCR-product is an amplification of the rearranged immunoglobulin 
heavy chain (IgH) gene. The product was inserted into a vector and subjected to sequence analysis. 
Through real time PCR analysis, the number of neoplastic peripheral lymphocytes could be assessed. 
The cytoreductive effect of the three cytostatic agents included in the protocol was assessed. This 
analysis could demonstrate that the cytoreductive efficacy of cyclophosphamide was less than the 
other agents, and that dogs who did not respond to cyclophosphamide had shorter first remission than 
dogs who responded to treatment (Sato et al., 2011).  
 
In addition to chemotherapy, treatment with anti-tumor antibodies is also available. However, 
rituximab had no inhibitory effect on cancer cells in-vitro (Impellizeri et al., 2006). Vaccination 
against cancer has been discussed and experiments are on-going, but this will not be discussed further 
in this text.  
 
It can be clinically difficult to determine if CR has been achieved on cellular and molecular level. PCR 
techniques and genotypic detection methods have been developed for use on humans to investigate if 
CR has been reached (Dölken et al., 2001). In veterinary medicine, these techniques are little 
investigated, but the use of thymidine kinase has in recent years improved the ability to detect and 
monitor patients with lymphoma by serum measurements (von Euler et al., 2004). LDH (lactate 
dehydrogenase) has also been used to monitor patients with an established diagnosis of lymphoma 
after the end of treatment (Marconato et al., 2010). 
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